

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
*in its capacity as elected Office*

<b>Date of mailing</b> (day/month/year) 14 November 2000 (14.11.00)	
<b>International application No.</b> PCT/EP00/03238	<b>Applicant's or agent's file reference</b> HF2042061PCT
<b>International filing date</b> (day/month/year) 11 April 2000 (11.04.00)	<b>Priority date</b> (day/month/year) 13 April 1999 (13.04.99)
<b>Applicant</b> DEL SOLDATO, Piero	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 26 October 2000 (26.10.00)


☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  Claudio Borton  Telephone No.: (41-22) 338.83.38
---	--



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

14

Applicant's or agent's file reference HF2042/061/PCT	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP00/03238	International filing date (day/month/year) 11/04/2000	Priority date (day/month/year) 13/04/1999
International Patent Classification (IPC) or national classification and IPC C07J41/00		
Applicant NICOX S.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  26/10/2000	Date of completion of this report  07.02.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Friebel, F  Telephone No. +49 89 2399 8552



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/03238

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

### Description, pages:

1-73 as originally filed

### Claims, No.:

1-12 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/03238

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1,2,4,7-12 (partially), 3,5,6.

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
  - ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
  - ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
  - ☒ no international search report has been established for the said claims Nos. 1,2,4,7-12 (partially), 3,5,6.
2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- ☐ the written form has not been furnished or does not comply with the standard.
  - ☐ the computer readable form has not been furnished or does not comply with the standard.

### IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/03238

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☒ not complied with for the following reasons:  
**see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☐ all parts.
- ☒ the parts relating to claims Nos. 1,2,4,7-12 (in part).

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	

### 2. Citations and explanations **see separate sheet**

**point III:**

As concerns the lack of clarity and lack of support issue it is emphasized that the IPEA fully agrees with the Search Examiner. The claims cover indeed an extremely large number of possible compounds. The many options, variables and possible permutations result in claims which are not only complex, but simply unclear (Art.6 PCT).

Search has been carried out for those parts of the claims which relate to the specific compounds of the examples consequently the present Report covers only those parts of the application.

**point VI:**

As concerns the non-unity objection reference is made to the detailed reasoning of the Search Examiner being part of the International Search Report.

**point V:**

Subject-matter of the queried examples are on the one hand side nitrooxy-nbutyl esters of ursodeoxycholy-ferulate and chenodesoxycholy-ferulate, respectively and on the other side pregnene-3,20-dione derivatives which carry at the C-21 position of the side chain an N-acetyl-S-(4-nitroxybutyroyl)cysteinyloxy moiety.

Such compounds are neither disclosed nor made obvious by the available prior art; see for instance the reference **WO 98/15568 (D1)** and **WO 97 41144 (D2)** which relate to the same technical field but do not disclose the specific bridging member (ferulate, cysteinyloxy) as proposed in the instant case. Novelty and inventive step are acknowledged; Art.33(2) (3) PCT.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>HF2042061PCT</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/EP 00/ 03238</b>	International filing date (day/month/year) <b>11/04/2000</b>	(Earliest) Priority Date (day/month/year) <b>13/04/1999</b>
Applicant  <b>NICOX S.A.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. \_\_\_\_\_

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

**INTERNATIONAL ARCH REPORT**

International application No.  
PCT/EP 00/03238

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1,2,4,7-12 (partially searched) 3,5,6 (not searched)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,2,4,7-12 (partially searched) 3,5,6 (not searched)

Please note that the subject matter searched in the context of the present application is limited both under according to Art.17(2)(a)(ii) PCT (for the reasons given below) and according to Art.17(3)(a) PCT (due to a lack of unity the reasons for which are given separately).

Present claims 1-12 relate to an extremely large number of possible compounds and pharmaceutical compositions and uses thereof. In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Furthermore, present claims 1-12 relate to compounds defined by reference to a desirable characteristic or property, namely the compounds are defined such that they attain a certain level of anti-oxidative activity evidenced according to test 4 or test 5 (both of which are elucidated in claim 1). Since this property (anti-oxidative activity) is in fact the problem to be solved by the compounds of the present application (see page 6, lines 2-7 of the description) - this means that the claimed compounds are defined in terms of their being a solution to this problem. It does not matter that there is also a generic Markush structural formula giving some degree of structural definition to the claimed compounds because the scope of this structural definition is extremely broad in terms of structural features (see above) the restriction of this very broad set of compounds by means of the desideratum is effectively the allegedly characterising feature of the claims (in particular independent compound claim 1) and so the technical meaning of this desideratum is essential in establishing the true scope of the claim according to Art.6 PCT. Since the skilled person is given no idea as to how to limit the broad scope of the compounds of claim 1 (and the uses and compositions thereof according to claims 10-12) to compounds which actually solve this problem, he must by necessity employ an inventive step according to Art.33(3) PCT in order to move from the disclosure of the claimed invention as given in claim 1 (and the uses and compositions thereof according to claims 10-12) to a viable product which actually solves this problem. Consequently the compounds of claim 1 are insufficiently disclosed according to Art.5 PCT to such an extent that no meaningful search is possible based on the full scope of claim 1.

Furthermore, the claims cover all compounds (claim 1) and uses and compositions (claims 10-12) having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (and their uses and compositions). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the specific compounds of the examples and their uses and compositions thereof.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,4,7-12 (in part)

Compounds of examples 1 and 2 - being the 3-(4-nitrooxy)-nbutyl ester of ursodeoxycholy1-ferulate and chenodesoxycholy1-ferulate respectively, their uses in the preparation of medicaments and compositions and pharmaceutical formulations containing them.

2. Claims: 1,2,4,7-12 (in part)

Compounds of examples 3-5 being:-

Example 3

(11.beta.)

11,17-Dihydroxy-21-'N-acetyl-S-(4-nitroxybutyroyl)cysteinylox  
y!-pregna-1,4-diene-3,20-dione

Example 4

(11.beta.)

11,17-Dihydroxy-21-'N-acetyl-S-(4-nitroxybutyroyl)cysteinylox  
y!-pregna-4-ene-3,20-dione

Example 5

(11.beta., 16.alpha.)

9-Fluoro-11,17-dihydroxy-21-'N-acetyl-S-(4-nitroxybutyroyl)cy  
steinyloxy!-16-methylpregna-1,4-dien-3,20-dione

, their uses in the preparation of medicaments and compositions and pharmaceutical formulations containing them.

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

SAMA, Daniele  
Sama Patents  
Via G.B. Morgagni, 2  
I-20129 Milano  
ITALIE

SAMA PATENTS

RECEIVED

## PCT

### NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing  
(day/month/year) 07.02.2001

Applicant's or agent's file reference  
HF2042/061/PCT

#### IMPORTANT NOTIFICATION

International application No.  
PCT/EP00/03238

International filing date (day/month/year)  
11/04/2000

Priority date (day/month/year)  
13/04/1999

Applicant  
NICOX S.A. et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Hebert, W

Tel. +49 89 2399-2152



# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>HF2042/061/PCT</b>	<div style="display: flex; justify-content: space-between;"> <div><b>FOR FURTHER ACTION</b></div> <div>See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)</div> </div>	
International application No. <b>PCT/EP00/03238</b>	International filing date ( <i>day/month/year</i> ) <b>11/04/2000</b>	Priority date ( <i>day/month/year</i> ) <b>13/04/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>C07J41/00</b>		
Applicant <b>NICOX S.A. et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☒ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  <b>26/10/2000</b>	Date of completion of this report  <b>07.02.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> <b>Tel. +49 89 2399 - 0 Tx: 523656 epmu d</b> <b>Fax: +49 89 2399 - 4465</b>	Authorized officer  <b>Friebel, F</b>  Telephone No. <b>+49 89 2399 8552</b>



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/03238

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

**Description, pages:**

1-73 as originally filed

**Claims, No.:**

1-12 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/03238

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1,2,4,7-12 (partially), 3,5,6.

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☒ no international search report has been established for the said claims Nos. 1,2,4,7-12 (partially), 3,5,6.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

**IV. Lack of unity of invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP00/03238

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
- ☐ complied with.
- ☒ not complied with for the following reasons:  
**see separate sheet**
4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:
- ☐ all parts.
- ☒ the parts relating to claims Nos. 1,2,4,7-12 (in part).

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1,2,4,7-12 (in part)
	No:	Claims	

**2. Citations and explanations  
see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP00/03238

**point III:**

As concerns the lack of clarity and lack of support issue it is emphasized that the IPEA fully agrees with the Search Examiner. The claims cover indeed an extremely large number of possible compounds. The many options, variables and possible permutations result in claims which are not only complex, but simply unclear (Art.6 PCT).

Search has been carried out for those parts of the claims which relate to the specific compounds of the examples consequently the present Report covers only those parts of the application.

**point VI:**

As concerns the non-unity objection reference is made to the detailed reasoning of the Search Examiner being part of the International Search Report.

**point V:**

Subject-matter of the queried examples are on the one hand side nitrooxy-nbutyl esters of ursodeoxycholy-ferulate and chenodesoxycholy-ferulate, respectively and on the other side pregnene-3,20-dione derivatives which carry at the C-21 position of the side chain an N-acetyl-S-(4-nitroxybutyroyl)cysteinyl moiety.

Such compounds are neither disclosed nor made obvious by the available prior art; see for instance the reference WO 98/15568 (D1) and WO 97 41144 (D2) which relate to the same technical field but do not disclose the specific bridging member (ferulate, cysteinyl) as proposed in the instant case. Novelty and inventive step are acknowledged; Art.33(2) (3) PCT.

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 00/03238

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1,2,4,7-12 (partially searched) 3,5,6 (not searched)  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,  
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1,2,4,7-12 (partially searched) 3,5,6 (not searched)

Please note that the subject matter searched in the context of the present application is limited both under according to Art.17(2)(a)(ii) PCT (for the reasons given below) and according to Art.17(3)(a) PCT (due to a lack of unity the reasons for which are given separately).

Present claims 1-12 relate to an extremely large number of possible compounds and pharmaceutical compositions and uses thereof. In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Furthermore, present claims 1-12 relate to compounds defined by reference to a desirable characteristic or property, namely the compounds are defined such that they attain a certain level of anti-oxidative activity evidenced according to test 4 or test 5 (both of which are elucidated in claim 1). Since this property (anti-oxidative activity) is in fact the problem to be solved by the compounds of the present application (see page 6, lines 2-7 of the description) - this means that the claimed compounds are defined in terms of their being a solution to this problem. It does not matter that there is also a generic Markush structural formula giving some degree of structural definition to the claimed compounds because the scope of this structural definition is extremely broad in terms of structural features (see above) the restriction of this very broad set of compounds by means of the desideratum is effectively the allegedly characterising feature of the claims (in particular independent compound claim 1) and so the technical meaning of this desideratum is essential in establishing the true scope of the claim according to Art.6 PCT. Since the skilled person is given no idea as to how to limit the broad scope of the compounds of claim 1 (and the uses and compositions thereof according to claims 10-12) to compounds which actually solve this problem, he must by necessity employ an inventive step according to Art.33(3) PCT in order to move from the disclosure of the claimed invention as given in claim 1 (and the uses and compositions thereof according to claims 10-12) to a viable product which actually solves this problem. Consequently the compounds of claim 1 are insufficiently disclosed according to Art.5 PCT to such an extent that no meaningful search is possible based on the full scope of claim 1.

Furthermore, the claims cover all compounds (claim 1) and uses and compositions (claims 10-12) having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (and their uses and compositions). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07J 41/00, A61K 31/575</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/61604</b>
			(43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/EP00/03238 (22) International Filing Date: 11 April 2000 (11.04.00) (30) Priority Data: MI99A000751          13 April 1999 (13.04.99)          IT (71) Applicant (for all designated States except US): NICOX S.A. [FR/FR]; 45, avenue Kléber, F-75116 Paris (FR). (72) Inventor; and (75) Inventor/Applicant (for US only): DEL SOLDATO, Piero [IT/IT]; Via Toti, 22, I-20052 Monza (IT). (74) Agents: SAMA, Daniele et al.; Sama Patents, Via G.B. Morgagni, 2, I-20129 Milano (IT).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: PHARMACEUTICAL COMPOUNDS  <div style="text-align: center;"> <math display="block">A-(B)_{b0}-C-N(O)_s \quad (I)</math> </div> <div style="text-align: center;"> <math display="block">\begin{array}{c} A-C_1-B_1 \\   \\ N(O)_s \end{array} \quad (II)</math> </div>			
(57) Abstract  Steroidal compounds or their salts having general formulas (I) and (II) wherein: s is an integer equal to 1 or 2, preferably s = 2; b0 = 0 or 1; A = R-, wherein R is the steroidal drug radical, C and C <sub>1</sub> are two bivalent radicals. The precursors of the radicals B and B <sub>1</sub> are such as to meet the pharmacological tests reported in the description.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

"PHARMACEUTICAL COMPOUNDS"

\* \* \* \* \*

The present invention relates to novel steroidal compounds for systemic use and non systemic use, and their compositions, to be used in the conditions of oxidative stress and/or endothelial dysfunctions. Specifically it relates to compounds with a steroidal structure having antiinflammatory, immunodepressive and angiostatic activity (the so called antiinflammatory steroids), or gastrointestinal activity.

The compounds according to the present invention result therapeutically useful in the treatment of morbid conditions wherein the steroidal products are generally used with greater benefit, in terms both of a better tolerability and/or efficacy.

By oxidative stress it is meant the generation of free radicals or radicalic compounds, which causes injury both of the cell and of that of the surrounding tissue (Pathophysiology: the biological basis for disease in adults and children, McCance & Huether 1998 pages 48-54).

By endothelial dysfunctions are meant those relating to the vasal endothelium. The damage of the vasal endothelium is known as one of those important events that can bring about a series of pathological processes affecting various organs and

body apparatuses, as described hereinafter (Pathophysiology: The biological basis for disease in adults and children, McCance & Huether 1998 page 1025).

As known, the oxidative stress and/or the endothelial dysfunctions are associated to various pathologies as reported hereinafter. The oxidative stress can also be caused by toxicity of a great variety of drugs, which significantly affects their performances.

Said pathological events are of a chronic, debilitating character and are very often typical of the elderly. As already said, in said pathological conditions the drugs used show a remarkably worsened performance.

Examples of pathological situations caused by the oxidative stress and/or by the endothelial dysfunctions, or present in elderly, are the following:

- For the cardiovascular system: myocardial and vascular ischaemia in general, hypertension, stroke, arteriosclerosis, etc.
- For the connective tissue: rheumatoid arthritis and connected inflammatory diseases, etc.
- For the pulmonary system: asthma and connected inflammatory diseases, etc.
- For the gastrointestinal system: ulcerative and non ulcerative dyspepsias, intestinal inflammatory diseases, etc.

- For the central nervous system: Alzheimer disease, etc.
- For the urogenital system: impotence, incontinence.
- For the cutaneous system: eczema, neurodermatitis, acne.
- The infective diseases in general (ref.: Schwarz-KB, Brady "Oxidative stress during viral infection: A review" Free radical Biol. Med. 21/5, 641-649 1996).

Further the ageing process can be considered as a true pathologic condition (ref. Pathophysiology: the biological basis for disease in adults and children, pages 71-77).

The known drugs when administered to patients having pathologies associated to oxidative stress and/or endothelial dysfunctions, show a lower efficacy and/or higher toxicity.

This happens for example with steroids.

Drug research is directed to find new molecules having an improved therapeutic index (efficacy/toxicity ratio) or a lower risk/benefit ratio, also for pathological conditions as those above mentioned, wherein the therapeutic index of a great number of drugs results lowered. In fact in the above mentioned conditions of oxidative stress and/or endothelial dysfunctions, many drugs show a lower activity and/or higher toxicity.

It is well known that steroids represent a first choice pharmacological intervention in the therapy of inflammatory diseases. This class of drugs, among which can be mentioned for example hydrocortisone, cortisone, prednisone, prednisolone, fludrocortisone, desoxycorticosterone, metilprednisolone,

triamcinolone, paramethasone, betamethasone, dexamethasone, triamcinolone acetonide, fluocinolone acetonide, beclomethasone, acetoxypregnelone, etc., elicits remarkable pharmaco-toxicological effects on different organs, and for this reason both their clinical use and its interruption cause a series of side effects, some of which very serious. See for example Goodman & Gilman, "The pharmaceutical Basis of Therapeutics" 9<sup>th</sup> ed., pages 1459-1465, 1996.

Among said toxic effects can be mentioned those affecting the bone tissue leading to an altered cellular metabolism and an high osteoporosis incidence; those affecting the cardiovascular system, generating an hypertensive response; those affecting the gastrointestinal apparatus giving gastric damages.

See for example Martindale "The extrapharmacopoeia", 30<sup>th</sup> ed., pages 712-723, 1993.

To the class of steroidal drugs belong also biliary acids, that have been used in the therapy of hepatic disorders and in biliary colics. Ursodesoxycholic acid is also used in some hepatic dysfunctions (hepatic cirrhosis of biliary origin, etc.). Their tolerability is strongly worsened in the presence of gastrointestinal complications (chronic hepatic damage, peptic ulcer, intestinal inflammation, etc.). Also in the case of biliary acids the oxidative stress remarkably affects drug performance: both the efficacy and the tolerability of

chenodeoxycholic and ursodesoxycholic acids are significantly reduced. In particular the unwanted effects on liver are found exalted. Among the steroidal compounds can be mentioned also estrogens for the treatment of dislipidaemias, hormonal troubles, female apparatus tumours treatment can be mentioned. Also said steroids show side effects as above mentioned, in particular at the hepatic level.

According to the above mentioned prior art it seems almost impossible to separate therapeutic activity from side effects, see Goodman et al, above mentioned, at p. 1474.

The steroidal compounds are completely different from the antiinflammatory non steroidal compounds from the chemical, pharmacological and biochemical point of view, since the pharmaco-toxicological mechanism of action of nonsteroidal antiinflammatory products is based on the inhibition of one or more of the cyclooxygenases (COX), while steroids do not influence COX and have more complex pharmaco-toxicological mechanisms of action not yet fully cleared.


Indeed it is well known that these two groups of drugs are classified in different classes in the pharmacopoeias.

The need was felt to have available steroids showing an improved therapeutic performance, i.e. endowed both of a lower toxicity and/or higher efficacy, so that they could be administered to patients in morbid conditions of oxidative stress and/or endothelial dysfunctions, without showing the

drawbacks of the drugs of the prior art.

It has been now surprisingly and unexpectedly found that the aforementioned technical problems shown in the administration of steroidal drugs to patients affected by oxidative stress and/or endothelial dysfunctions, or to the elderly in general, are solved by a new class of drugs as described hereinafter.

An object of the invention are steroidal compounds or their salts having the following general formulas (I) and (II):



wherein:

s = is an integer equal to 1 or 2, preferably s = 2;

b0 = 0 or 1;

A = R-T<sub>1</sub>-, wherein R is the steroidal drug radical as defined hereunder,

B = -T<sub>B</sub>-X<sub>2</sub>-T<sub>BI</sub>- wherein

T<sub>B</sub> and T<sub>BI</sub> are equal or different;

T<sub>B</sub> = (CO) when the reactive function in the precursor steroid is -OH; T<sub>B</sub> = X when the reactive function in the precursor steroid is -COOH;

X = O, S, NR<sub>1C</sub>, R<sub>1C</sub> is H or a linear or branched alkyl having from 1 to 5 carbon atoms, or a free valence;


T<sub>BI</sub> = (CO)<sub>tx</sub> or (X)<sub>txx</sub>, wherein tx and txx have the value of 0 or 1; with the proviso that tx = 1 when txx = 0, tx = 0 when txx = 1; X is as above defined;

$X_2$  is a bivalent bridging bond as defined hereunder;

C is the bivalent radical  $-T_C-Y-$  wherein

$T_C = (CO)$  when  $tx = 0$ ,  $T_C = X$  when  $txx = 0$ , X being as above defined;

Y is:



wherein:

$nIX$  is an integer between 0 and 3, preferably 1;

$nIIX$  is an integer between 1 and 3, preferably 1;


$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$ , equal to or different from each other are H or a linear or branched  $C_1$ - $C_4$  alkyl; preferably  $R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$  are H.

$Y^3$  is a saturated, unsaturated or aromatic heterocyclic ring containing at least one nitrogen atom, preferably one or two nitrogen atoms, said ring having 5 or 6 atoms.


or Y is  $Y_0$ , selected from the following:

- an alkyleneoxy group  $R'O$  wherein  $R'$  is linear or branched when possible  $C_1$ - $C_{20}$ , preferably having from 1 to 6 carbon atoms, most preferably 2-4 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylenic ring one or more carbon atoms can be substituted with heteroatoms, the ring



can have side chains of R' type, R' being as above defined; or





wherein  $n_3$  is an integer from 0 to 3 and  $n_{3'}$  is an integer from 1 to 3;



wherein  $n_3$  and  $n_{3'}$  have the above mentioned meaning



wherein  $n_f$  is an integer from 1 to 6 preferably from 1 to 4;



wherein  $\text{R}_{1f} = \text{H}, \text{CH}_3$  and  $n_f$  is an integer from 1 to


6; preferably from 1 to 4;

preferably  $Y = -Y_0 = R'O-$  wherein  $R'$  is as above defined;

preferably  $R'$  is a  $C_1-C_6$  alkylene;



wherein:




wherein  $T_{CI}$  and  $T_{CII}$  are equal or different,

$T_{CI} = (CO)$  when the reactive function of the precursor steroid is  $-OH$ ,  $T_{CI} = X$  when the reactive function of the precursor steroid is  $-COOH$ ,  $X$  being as above defined;


$T_{CII} = (CO)_{tI}$  or  $(X)_{tII}$ , wherein  $tI$  and  $tII$  have the 0 or 1 value; with the proviso that  $tI = 1$  when  $tII = 0$ ;  $tI = 0$  when  $tII = 1$ ;  $X$  is as above defined;

$Y'$  is as  $Y$  above defined, but with three free valences instead of two, preferably it is selected from the following:


- a  $-R'O-$  group wherein  $R'$  is linear or branched  $C_1-C_{20}$ , preferably having from 1 to 6 carbon atoms, most preferably 2-4, or a saturated, optionally substituted, ring having from 5 to 7 carbon atoms;
- or




wherein  $n_3$  is an integer from 0 to 3 and  $n_3'$  is an integer from 1 to 3;




wherein  $n_3$  and  $n_3'$  have the above mentioned meaning;




wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;



wherein  $n_3'$  is an integer from 1 to 6 preferably from 1 to 4; wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;



wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;




wherein  $R_{1f} = H, CH_3$  and  $n_3$  is an integer from 1 to 6; preferably from 1 to 4; wherein one hydrogen atom

on one of the carbon atoms is substituted by a free valence;

preferably  $Y' = -R'O-$  wherein R' is a linear or branched  $C_2-C_4$ , the oxygen which in Y' is covalently linked to the  $-N(O)_s$  group is at the end of the free bond indicated in  $C_1$  formula;

or  $Y' = Y_0$  as defined in (I) but with three free valences instead of 2;




wherein  $X_{2a}$  is a monovalent radical,

$T_{BII} = (CO)$  when  $tI = 0$ ,  $T_{BII} = X$  when  $tII = 0$ , X being as above defined;

- $X_2$ , bivalent radical, is such that the corresponding precursor of B:  $-T_3 - X_2 - T_{3-}$  meets test 4 or test 5, precursor in which the  $T_3$  and  $T_{3-}$  free valences are each saturated with OZ, with Z or with  $-Z^I-N-Z^{II}$ ,  $Z^-$  and  $Z^{--}$  being equal or different and have the Z values as above defined, depending on whether  $T_3$  and/or  $T_{3-} = CO$  or X, in connection with the values of t, t', tx and txx;
- the C precursor when  $b0 = 0$  is of  $-T_C-Y-H$  type wherein the  $T_C$  free valence is saturated with OZ, Z, or with  $-Z^I-N-Z^{II}$ ,  $Z^I$  and  $Z^{--}$  being as above defined and is such as to meet test 5;
- $X_{2a}$  monovalent radical, such that the corresponding

precursor of  $B_1 - T_{BII} - X_{2a}$  meets test 4 or test 5,  
 precursor wherein the  $T_{BII}$  free valence is saturated  
 with  $OZ$  or with  $Z$  or with  $-Z^I-N-Z^{II}$ ,  $Z^I$  and  $Z^{II}$   
 being equal or different and having the  $Z$  values as  
 above defined, depending on whether  $T_{BII} = CO$  or  $X$ ,  
 in connection with the  $tI$  and  $tII$  values;


$A = R-$ , has the following structure:




wherein in substitution of the hydrogens of the  $CH$  groups or of  
 the two hydrogens of the  $CH_2$  groups mentioned in the general  
 formula, the following substituents can be present:

in position 1-2: there may be a double bond;

in position 2-3: there may be the following substituent:




in position 2: there may be Cl, Br;  
 in position 3: there may be CO, -O-CH<sub>2</sub>-CH<sub>2</sub>-Cl, OH;  
 in position 3-4: there may be a double bond;  
 in position 4-5: there may be a double bond;  
 in position 5-6: there may be a double bond;  
 in position 5-10: there may be a double bond;  
 in position 6: there may be Cl, F, CH<sub>3</sub>, -CHO;  
 in position 7: there may be Cl, OH;  
 in position 9: there may be Cl, F;  
 in position 11: there may be OH, CO, Cl, CH<sub>3</sub>;  
 in position 16: there may be CH<sub>3</sub>, OH, =CH<sub>2</sub>;  
 in position 17: there may be OH, CH<sub>3</sub>, OCO(O)<sub>ua</sub>(CH<sub>2</sub>)<sub>va</sub>CH<sub>3</sub>, C≡CH  
 or



wherein ua is an integer equal to 0 or 1, va is an integer from 0 to 4;

in position 16-17: there may be the following groups:




R and R', equal to or different from each other, can be hydrogen or linear or branched alkyls from 1 to 4 carbon atoms,

preferably  $R = R' = CH_3$ ;

$R''$  is  $-(CO-L)_t-(L)_{t2}-(X_0^I)_{t1}-$


wherein  $t$ ,  $t1$  and  $t2$  are integers equal to or different from each other, equal to 0 or 1, with the proviso that when  $t = 0$   $t2 = 1$  and when  $t = 1$   $t2 = 0$ , and that  $t$  and  $t1$ , or  $t2$  and  $t1$ , cannot contemporaneously be equal to 0 when A does not contain -OH groups;

the bivalent bridging group L is selected from:



wherein  $na$ ,  $n'a$ , and  $n''a$ , equal to or different from each other, are integers from 0 to 6, preferably 1-3;  $nb$ ,  $n'b$ ,  $n''b$  and  $n''''b$ , equal to or different from each other, are integers equal to 0 or 1;  $R_4$ ,  $R_5$ , equal to or different from each other, are selected from H, linear or branched alkyl from 1 to 5 carbon atoms, preferably from 1 to 3;

$X_0^I$  is X as above defined, but  $R_{1c}$  is a linear or branched alkyl from 1 to 10 carbon atoms, or equal to  $X_2^I$  wherein  $X_2^I$  is equal to OH,  $CH_3$ , Cl,  $N(-CH_2-CH_3)_2$ ,  $SCH_2F$ , SH, or



wherein test 4 is the following: it is an analytical determination carried out by adding portions of methanol

solutions of the precursor of B or B<sub>1</sub> at a 10<sup>-4</sup> M concentration, to a methanol solution of DPPH (2,2-diphenyl-1-picryl hydrazyl - free radical); after having maintained the solution at room temperature away from light for 30 minutes, it is read the absorbance at the wave length of 517 nm of the test solution and of a solution containing only DPPH in the same amount as in the test solution; and then the inhibition induced by the precursor towards radical production by DPPH is calculated as a percentage by means of the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein A<sub>s</sub> and A<sub>c</sub> are respectively the absorbance values of the solution containing the test compound + DPPH and that of the solution containing only DPPH; the acceptance criterium of the compounds according to this test is the following: test 4 is met by B or B<sub>1</sub> precursor compounds if the inhibition percentage as above defined is higher than or equal to 50%;

wherein test 5 is the following: it is an analytical determination carried out by adding aliquots of 10<sup>-4</sup> M methanol solutions of the precursor of B or B<sub>1</sub> or of C = -T<sub>C</sub>-Y-H, having the free valence saturated as above indicated, to a solution formed by admixing a 2 mM solution of desoxyribose in water with 100 mM of phosphate buffer and 1 mM of the salt Fe<sup>II</sup>(NH<sub>4</sub>)<sub>2</sub>(SO<sub>4</sub>)<sub>2</sub>; after having thermostatted the solution at 37°C for one hour, aliquots of aqueous solutions of trichloroacetic acid 2.8% and of thiobarbituric acid 0.5 M are

added, in the order, heating is effected at 100°C for 15 minutes and the absorbance of the tested solutions is then read at 532 nm; the inhibition induced by the precursor of B or B<sub>1</sub> or C = -T<sub>C</sub>-Y-H with respect to radical production by Fe<sup>II</sup> is calculated as a percentage by means of the following formula:


$$(1 - A_s/A_c) \times 100$$

wherein A<sub>s</sub> and A<sub>c</sub> are respectively the absorbance values of the solution containing the tested compound and the iron salt and that of the solution containing only the iron salt, the compound meets test 5 when the inhibition percentage as above defined of the precursor of B or B<sub>1</sub> or C = -T<sub>C</sub>-Y-H, having the free valence saturated as above indicated, is higher than or equal to 50%; provided that in the compounds of formula (I) are excluded the drugs with A = R-, wherein R is as above defined, when b<sub>0</sub> = 0 and C = -T<sub>C</sub>-Y<sub>0</sub>- wherein the free valence of Y<sub>0</sub> is saturated as indicated above, s = 1 or 2.


Preferably the B or B<sub>1</sub> precursor compound (precursor of the X<sub>2</sub> or X<sub>2a</sub> radical in formulas (I) and (II) respectively) which meets test 4, is selected from the following classes of compounds:

- Aminoacids, selected from the following: L-carnosine (formula CI), anserine (CII), selenocysteine (CIII), selenomethionine (CIV), penicillamine (CV), N-acetylpenicillamine (CVI), cysteine (CVII), N-acetylcysteine (CVIII), glutathione (CIX) or its esters, preferably ethyl


or isopropyl ester:




(CI)




(CII)




(CIII)




(CIV)




(CV)




(CVI)



(CVII)




(CVIII)




(CIX)

- hydroxyacids, selected from the following: gallic acid


(formula DI), ferulic acid (DII), gentisic acid (DIII), citric acid (DIV), caffeic acid (DV), hydrocaffeic acid (DVI), p-coumaric acid (DVII), vanillic acid (DVIII), chlorogenic acid (DIX), kynurenic acid (DX), syringic acid (DXI):




(DI)




(DII)




(DIII)




(DIV)




(DV)




(DVI)




(DVII)




(DVIII)



(DIX)




(DX)




(DXI)


- Aromatic and heterocyclic mono- and polyalcohols, selected from the following: nordihydroguaiaretic acid (EI), quercetin (EII), catechin (EIII), kaempferol (EIV), sulphurethyne (EV), ascorbic acid (EVI), isoascorbic acid (EVII), hydroquinone (EVIII), gossypol (EIX), reductic acid (EX), methoxyhydroquinone (EXI), hydroxyhydroquinone (EXII), propyl gallate (EXIII), saccharose (EXIV), vitamin E (EXV), vitamin A (EXVI), 8-quinolol (EXVII), 3-tert-butyl-4-hydroxyanisole (EXVIII), 3-hydroxyflavone (EXIX), 3,5-tert-butyl-p-hydroxytoluene (EXX), p-tert-butyl phenol (EXXI), timolol (EXXII), xibornol (EXXIII), 3,5-di-ter-butyl-4-hydroxybenzyl-thioglycolate (EXXIV), 4'-hydroxybutyranilide (EXXV), guaiacol (EXXVI), tocol (EXXVII), isoeugenol (EXXVIII), eugenol (EXXIX), piperonyl alcohol (EXXX), allopurinol (EXXXI), conyferyl alcohol (EXXXII), 4-hydroxyphenetyl alcohol (EXXXIII), p-coumaric alcohol (EXXXIV), curcumin (EXXXV):




(EI)




(EII)




(EIII)




(EIV)




(EV)




(EVI)




(EVII)




(EVIII)




(EIX)




(EX)




(EXI)




(EXII)




(EXIII)




( EXIV )




( EXV )




( EXVI )




(EXVII)




( EXVIII )




( EXIX )




( EXXI )




(EXX)




(EXXII)




(EXXIII)




(EXXIV)




(EXXV)




(EXXVI)




(EXXVII)




(EXXXI)




(EXXVIII)




(EXXIX)




(EXXX)




(EXXXII)



(EXXXIII)




(EXXXIV)




(EXXXV)


- aromatic and heterocyclic amines, selected from the following: N, N'-diphenyl-p-phenylenediamine (MI), ethoxyquin (MII), thionine (MIII), hydroxyurea (MIV):




(MI)



(MII)




(MIII)




(MIV)


- Compounds containing at least a free acid function, selected from the following: 3,3'-thiodipropionic acid (NI), fumaric acid (NII), dihydroxymaleic acid (NIII), thiocctic acid (NIV), edetic acid (NV), bilirubin (NVI), 3,4-methylenedioxcinnamic acid (NVII), piperonylic acid (NVIII):



(NI)




(NII)




(NIII)




(NIV)




(NV)



(NVI)



(NVII)




(NVIII)


The above mentioned substances precursors of B or B<sub>1</sub> are prepared according to the known methods in the prior art, described, for example, in "The Merck Index, 12a Ed. (1996), herein incorporated by reference. When available, the corresponding isomers and optical isomers can be used.

Preferably the precursor compound of B or of B<sub>1</sub> (precursor of the X<sub>2</sub> or X<sub>2a</sub> radical in formulas (I) and (II) respectively) which meets test 5, is selected from the following compounds:


- Aminoacids: aspartic acid (PI), histidine (PII),  
5-hydroxytryptophan (PIII), 4-thiazolidincarboxylic acid (PIV), 2-oxo-4-thiazolidincarboxylic acid (PV)




(PI)




(PII)



(PIII)




(PIV)



(PV)


mono and polyalcohols or thiols: 2-thiouracil (QI), 2-mercaptoethanol (QII), esperidine (QIII), secalciferol (QIV), 1- $\alpha$ -OH vitamin D2 (QV), flocalcitriol (QVI), 22-oxacalcitriol (QVII), the vitamin D3 derivative esterified with the vitamin A radical (QVIII), the formula (QIX) compound, 24,28-methylene-1 $\alpha$ -hydroxyvitamin D2 (QX) the compound derived from 1 $\alpha$ ,25-dihydroxyvitamin D2 (QXI), 2-mercaptoimidazol (QXII)








(QI)




(QII)




(QIII)







(QIX)



(QX)




(QXII)



(QXI)

- succinic acid (RI)



(RI)

The precursor compounds of B or B<sub>1</sub> of the above mentioned groups P, Q and R are prepared according to the known methods in the prior art and described for example in "The Merck Index", 12<sup>a</sup> Ed. (1996), herein incorporated by reference.

The vitamin D3 derivative with retinoic acid (QVIII) is prepared as described in JP 93039261 (ref. C.A. 119 117617); the formula (QIX) compound according to EP 562497; 24,28-

methylene-1 $\alpha$ -hydroxyvitamin D2 (QX) according to EP 578494; the derivative compound of dehydroxyvitamin D2 (QXI) according to EP 549,318.

The precursors of B or B<sub>1</sub> which meet test 4, are preferred.

The tests carried out to identify the precursors of B or B<sub>1</sub> are in detail the following:

Test 4 is a colorimetric test which affords to establish whether the precursors of B or B<sub>1</sub> inhibit the production of radicals from DPPH (2,2-diphenyl-1-picryl-hydrazyl) (M.S. Nenseter et Al., Atheroscler. Thromb. 15, 1338-1344, 1995). 100  $\mu$ M solutions in methanol of the tested substances are prepared, and an aliquot of each of said solutions is added to a DPPH solution in methanol 0.1 M. After having stored the solutions at room temperature away from light for 30 minutes, their absorbances are read at the wave length of 517 nm, together with that of the corresponding DPPH solution at the same concentration. The absorbance decrease with respect to that of the solution of DPPH at the same concentration of the test solutions is determined. The effectiveness of the tested compound in inhibiting formation of radicals by DPPH is expressed by the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein A<sub>s</sub> and A<sub>c</sub> are respectively the absorbance values of the solution containing the test compound together with DPPH and of

the solution containing only DPPH; the compounds precursor of B or B<sub>1</sub> meet test 4 when the inhibition percentage of radical production from DPPH, expressed as a percentage according to the above equation, is higher than or equal to 50% at the indicated concentration ( $10^{-4}$  M).

If the precursors of B or B<sub>1</sub> do not meet test 4, test 5 is carried out.


Test 5 is a colorimetric test wherein 0.1 ml aliquots of  $10^{-4}$  M methanolic solutions of the tested products are added to test tubes containing a solution formed by 0.2 ml of 2 mM desoxyribose, 0.4 ml of phosphate buffer pH 7.4 100 mM and 0.1 ml of 1 mM  $\text{Fe}^{2+}(\text{NH}_4)_2(\text{SO}_4)_2$  in 2mM HCl. The test tubes are then maintained at 37°C for one hour. Then in each test tube 0.5 ml of a 2.8% solution in trichloroacetic acid water and 0.5 ml of an aqueous 0.1 M solution of thiobarbituric acid are added, in the order. A reference blank is formed by adding to a test tube containing only the above described aqueous solution of reactants 0.1 ml of methanol. The test tubes are closed and heated in an oil bath at 100°C for 15 minutes. A pink coloration is developed the intensity of which is proportional to the quantity of desoxyribose undergone to radical oxidative degradation. The solutions are cooled at room temperature and their absorbances are read at 532 nm against the blank. The inhibition induced by the precursor of B or B<sub>1</sub> or C =  $-T_c - Y - H$  in comparison with the radical production by  $\text{Fe}^{\text{II}}$  is determined

by means of the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the tested compound + the iron salt and that of the solution containing only the iron salt, the compound meets test 5 when the inhibition percentage of radical production as above defined from the precursor of B or B<sub>1</sub> or C =  $-T_c - Y-H$  is higher than or equal to 50%.

$Y^3$  in formula (III) is preferably selected from the following:



The most preferred of  $Y^3$  is Y12 (pyridyl) substituted in positions 2 and 6. The bonds can find also in asymmetric position, for example Y12 (pyridyl) can be substituted also in position 2 and 3; Y1 (pyrazol) may be 3,5-disubstituted.

The compounds according to the present invention of formula (I) and (II) can be transformed into the corresponding salts. For example one way to form salts is the following: when in the molecule one nitrogen atom sufficiently basic to be salified, in organic solvent such as for example acetonitrile,

tetrahydrofuran, is present, it is reacted with an equimolecular amount of the corresponding organic or inorganic acid.

Preferably in the formula of the invention compounds Y or Y' of formula (III) is present.

Examples of organic acids are: oxalic, tartaric, maleic, succinic, citric acids.

Examples of inorganic acids are: nitric, hydrochloric, sulphoric, phosphoric acids.

In the steroid precursors preferably  $R'' = -CO-CH_2OH$ ,  $-CH(CH_3)-CH_2-CH_2-COOH$ .

Among the steroid precursors those having the hydroxyl function in position 3 or in position 11, or having in  $R''$  an hydroxyl or carboxylic function in terminal position, are preferred.

The steroid precursors of A which can be mentioned and which are preferred, are those listed hereinunder, obtainable according to the processes known in the art.

As precursors and respective processes, those for example described in The Merck Index, ed. 12 of 1996, herein incorporated by reference, can be mentioned. The precursors (according to the Merck nomenclature) are the following, wherein  $H_2$ , H, R, R', R'' have the meaning mentioned in the compounds listed herein: Budesonide, Hydrocortisone, Alclomethasone, Algestone, Beclomethasone, Betamethasone, Chloro-

prednisone, Clobetasol, Clobetasone, Clocortolone, Cloprednol, Cortisone, Corticosterone, Deflazacort, Desonide, Desoximethasone, Dexamethasone, Diflorasone Diflucortolone, Difluprednate, Fluazacort, Flucloronide, Flumethasone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluocortyn Butyl, Fluocortolone, Fluorometholone, Fluperolone Acetate, Fluprednidene Acetate, Fluprednisolone, Flurandrenolide, Formocortal, Halcinonide, Halobetasol Propionate, Halomethasone, Halopredone Acetate, Hydrocortamate, Loteprednol Etabonate, Medrysone, Meprednisone, Methylprednisolone, Momethasone Furoate, Paramethasone, Prednicarbate, Prednisolone, Prednisolone 25-Diethylaminoacetate, Prednisolone Sodium Phosphate, Prednisone, Prednival, Prednylidene, Rimexolone, Triamcinolone, Triamcinolone Acetonide, 21-Acetoxyprogesterone, Cortivazol, Amcinonide, Fluticasone Propionate, Mazipredone, Tixocortol, Triamcinolone Hexacetonide, Ursodesoxycholic acid, Chenodeoxycholic acid, Mitatrienediol, Moxestrol, Ethynylestradiol, Estradiol, Mestranol.

Unexpectedly the invention products of the formulas (I) and (II), in conditions of oxidative stress, have an improved therapeutic index compared with the precursor steroids.

For illustrative purposes the above mentioned tests are referred to the following compounds (see the tables attached to the description):

Test 4 (test for the precursor of B and B<sub>1</sub>, ref. Table III)

N-acetylcysteine inhibits of 100% radical production from DPPH, therefore it meets test 4 and it can be used as precursor of B or B<sub>1</sub>.

4-thiazolidincarboxylic acid does not inhibit radical production from DPPH, therefore it does not meet test 4: it can be used as precursor of B or B<sub>1</sub> if it meets test 5.

Test 5 (test for the precursor of B and B<sub>1</sub> or of C= -T<sub>c</sub>-Y-H, ref. Table IV)

4-thiazolidincarboxylic acid meets test 5 since the inhibition is of 100%. Therefore the compound can be used as precursor of B or B<sub>1</sub> in formula (I).

The compounds of the invention can be used in the same therapeutic indications of the precursor drug with the above mentioned advantages.

The compounds of formula (I) or (II) are prepared by synthesis methods mentioned hereinunder.

The choice of the reactions for each method depends on the reactive group present in the steroid molecule, in the precursor compound of B or B<sub>1</sub>, which can be, as above mentioned, bivalent or monovalent, and in the precursor compound of C.

The reactions are carried out with well known methods in the prior art, which allow to obtain bonds among the steroid, the precursor compound of B or B<sub>1</sub> and the precursor compound of

C as above defined.

When the reactive function of the steroid (for example -COOH, -OH) is involved in a covalent bond, for example of ester, amide, ether type, said function can be restored with the well known methods in the prior art.



Some synthesis schemes for obtaining the compounds of the invention are reported hereinafter:

A) Synthesis of the compounds of formula (I).

1. Synthesis of the compound obtained by reaction between the steroid and the compound precursor of B.

1a. When the steroid contains a carboxylic function (general formula: R-COOH) and the functional group of the precursor compound of B which binds itself to the carboxylic function has the formula XZ, X being as above defined and Z = H, the effected reactions depend on the nature of the second reactive group present in the precursor compound of B.

1a.1 When the second reactive group present in the precursor compound of B is a carboxylic group, the synthesis general scheme expects the initial formation of the acyl halide of the R-COHal steroid (Hal = Cl, Br) and the subsequent reaction with the HX group of the precursor compound of B:



$X_2$ ,  $T_B$  being as above defined.

When in the two reaction compounds other functional groups COOH and/or HX are present, they must be protected before the reaction according to the methods known in the prior art; for example as described in the publication by Th. W. Greene: "Protective groups in organic synthesis", Harvard University Press, 1980.


The RCOHal acylhalide is prepared according to the known methods in the prior art, for example by thionyl or oxalyl chloride,  $P^{III}$  or  $P^V$  halides in inert solvents under the reaction conditions, such as for example toluene, chloroform, DMF, etc.

Specifically, when the HX group of the precursor compound of B is  $NH_2$ , or OH or SH, the steroid of formula R-COOH is first converted into the corresponding acyl halide RCOHal, as above mentioned, and then reacted with the HX group of the precursor compound of B in the presence of an organic base, such as triethylamine, pyridine, etc. using an inert solvent in the reaction conditions such as toluene, tetrahydrofuran, etc. at a temperature in the range 0°C-25°C.

Alternatively to the previous synthesis, the steroid of formula R-COOH can be treated with an agent activating the carboxyl group selected from N,N'-carbonyldiimidazol (CDI), N-hydroxybenzotriazol and dicyclohexylcarbodiimide

in solvent such as for example DMF, THF, chloroform etc. at a temperature in the range  $-5^{\circ}\text{C}$  -  $50^{\circ}\text{C}$  and the obtained compound reacted in situ with the reactive function of the precursor compound of B for obtaining the compound of formula (IA.1).



1a.2 When the precursor compound of B contains two functional groups XZ, equal to or different from each other, X being as above defined and Z = H, the steroid having formula R-COOH is first treated with an agent activating the carboxyl group, as above described in 1a.1, and then with the precursor compound of B, after having protected one of the two reactive HX groups, for example with acetyl or tert-butyloxycarbonyl, restoring the initial function at the synthesis end. The scheme is the following:





wherein X, T<sub>B</sub>, X<sub>2</sub> are as above defined and G is a protective group of the HX function.

## 2. Nitroxyderivative synthesis.



2a.1 When the compound obtained at the end of the previous step 1a. has formula (IA.1), the acid can be converted into the corresponding sodic salt and one can then follow the known prior art methods for preparing the final compound, for example according to one of the following synthesis schemes:



wherein  $T_3$ ,  $X_2$ ,  $T_{BI}$ ,  $T_C$  are as above defined,  $R_4$  is selected from Cl, Br, Y is as above defined,  $X_1$  is the Y radical free from the oxygen atom,  $R_3$  is Cl, Br, Iodine, OH. If  $R_3 = OH$  the compound of formula (1A.1b) is subjected to halogenation, for example with  $PBr_3$ ,  $PCl_5$ ,  $SOCl_2$ ,  $PPh_3 + I_2$ , and then reacted with  $AgNO_3$  in organic solvent such as acetonitrile, tetrahydrofuran. If  $R_3$  is Cl, Br, Iodine, the compound of formula (1A.1b) is directly reacted with  $AgNO_3$  as above mentioned.



C.)




wherein  $R_5 = OH$  or  $NHR_{1C}$ ,  $R_{1C}$ ,  $R_3$  and the other symbols being as above defined.

When  $X_1$  is a linear  $C_4$  alkyl, the corresponding acid  $R-T_B-X_2-COOH$  is reacted with triphenylphosphine in the presence of an halogenating agent such as  $CBr_4$  or N-bromosuccinimide in tetrahydrofuran obtaining the compound

(1A.1c) wherein  $R_3 = \text{Br}$ .

2a.2 When the compound obtained at the end of the previous step 1a. has formula (IA.2), the corresponding nitroxyderivative is obtained by treating an halogen-carboxylic acid of formula  $\text{Hal-X}_1\text{-COOH}$ ,  $X_1$  being as above defined, first with an agent activating the carboxyl group as described in 1A.1, and then with the compound of formula (IA.2), obtaining an halogen derivative, which is isolated and then dissolved in organic solvent, (ref. paragraph 2a.1), and treated with silver nitrate. The global reaction scheme is the following:



wherein  $T_B$ ,  $X_2$ ,  $T_{BI}$ ,  $T_C$ ,  $Y$  are as above defined.



Alternatively, the halide  $\text{Hal-X}_1\text{-COCl}$  can be used, wherein  $\text{Hal}$  is preferably bromine, which is let react with the compound of formula (IA.2).

1b. When the reactive function of the steroid is  $-\text{OH}$  (general formula:  $\text{R-OH}$ ), the two functional groups present on the precursor compound of B can be the following:

1b.1 A carboxylic group, which reacts with the steroid  $\text{OH}$  function, and a  $\text{HX}$  group, the latter reactive group of the precursor compound of B being equal to or different from

the steroid functional group. The formula of the precursor compound of B is of the H-X-X<sub>2</sub>-COOH type, wherein X and X<sub>2</sub> are as above defined.

The H-X- function of the precursor compound of B is protected according to the known prior art methods and the carboxyl is reacted, as above mentioned, according to the following scheme:



At the end of the reaction the HX function of the precursor compound of B is restored.

1b.2 When the precursor compound of B contains two carboxylic groups, it is treated with an equimolar amount of an agent activating the carboxyl group under the conditions previously described in 1a.1, and then reacted with the reactive OH function of the steroid molecule. Possible other reactive functions of HX type present in the two compounds must be carefully protected as previously mentioned. Lastly a compound of formula R-T<sub>3</sub>-X<sub>2</sub>-COOH (1B.2) is obtained.

2b. Nitroxyderivative synthesis.


2b.1 To obtain the final nitroxyderivative starting from the compound of formula R-T<sub>B</sub>-X<sub>2</sub>-X-H (1B.1), obtained at the end of the synthesis described in 1b.1, the (1B.1) compound is reacted with a halogenacid of formula Hal-X<sub>1</sub>-

COOH which has been treated as previously described in paragraph 1a.1, or with the corresponding halogenacid chloride, the resulting compound is dissolved in organic solvent, for example acetonitrile or tetrahydrofuran and reacted with silver nitrate.

2b.2 To obtain the final nitroxyderivative starting from the compound of formula  $R-T_3-X_2-COOH$  (1B.2), obtained at the end of the synthesis described in 1b.2, the acid is transformed into the corresponding sodic salt, it is reacted with a  $R_4-X_1-R_3$  compound, previously defined in the reaction A. scheme of paragraph 2a.1, obtaining according to the same process therein mentioned the final nitroxyderivative. Alternatively, when  $X_1$  is a linear  $C_4$  alkyl, the acid (1B.2) is reacted with triphenyl-phosphine in the presence of an halogenating agent such as  $CBBr_4$  or N-bromosuccinimide in tetrahydrofuran and the resulting compound dissolved in organic solvent for example acetonitrile, tetrahydrofuran, is reacted with silver nitrate.

2b.3 Alternatively to the synthesis process according to 1b.1 and 2b.1, it is possible to react in a first step the HX-function of the precursor compound of B  $HX-X_2-COOH$  with the acyl chloride of an halogenacid of formula  $Hal-X_1-CO-Cl$ , wherein Hal is preferably Br, and subsequently the carboxylic function of the so obtained compound, with the

steroid of formula R-OH. In the third and last step the Hal group is substituted with -ONO<sub>2</sub> according to the process described in 2b.1. The reaction scheme is the following:



wherein T<sub>C</sub>, T<sub>B1</sub>, T<sub>B</sub>, X<sub>2</sub>, X<sub>1</sub>, Y are as above defined.


In the previous scheme the nitration can alternatively be carried out on the acid compound of formula (2B.3).

In the above mentioned processes the steroid reaction with the precursor of B for the compounds of formula (I) is not carried out when b<sub>0</sub> = 0, and in the reaction with the precursor compound of C the steroid with its reactive function is directly used.

#### B) Synthesis of compounds of formula (II).

1a. When the steroid reactive function is a carboxylic group and the precursor compound of B<sub>1</sub> contains only one functional reactive group of formula XH, X being as above defined, the steroid is initially converted into the corresponding acyl-halide (RCOCl), or treated with an agent activating the carboxyl group as described in 1a.1, and then reacted with the HX function of an halogen-acid compound, said function being equal to or different from that present on the precursor compound of B<sub>1</sub>, said

halogen-acid having the formula:





wherein  $X_1'$  is  $Y'$  as above defined without the oxygen atom through which the  $-\text{NO}_2$  group is linked,  $X$  and  $\text{Hal}$  are as above defined.

The compound (IIA.1) can be obtained with the known method of the prior art.


For example when  $X = \text{NH}$ , it can be obtained from the corresponding hydroxy-aminoacid, by protecting the aminic group by the corresponding tert-butyl-oxycarbonyl derivative and transforming the hydroxyl function into halogen group as described for the compound halogenation (1A.1b) in 2a.1.

The free carboxylic function of the compound resulting from the reaction with the steroid molecule is reacted with the function present in the molecule of the precursor of  $B_1$ , as previously illustrated in 1a.1 for the reaction between the steroid of formula  $R\text{-COOH}$  and the precursor compound of  $B$ . In the final step the halogen atom ( $\text{Hal}$ ) present on the radical  $X_1$  is substituted with an  $\text{ONO}_2$  group by adding  $\text{AgNO}_3$  to an organic solution of the compound. The reaction scheme is the following, exemplified starting from the  $\text{RCOCl}$  halide:






- 1b. When the steroid reactive function is a OH group and the precursor compound of B<sub>1</sub> contains a reactive group of general formula XH, HX wherein X is as above defined, being equal to or different from OH, the synthesis is carried out starting from an halogendiacid compound of formula




X<sub>1</sub>' being as above defined, said compound being prepared from the corresponding hydroxy-diacid as described for the halogenation of the compound (1A.1b) in 2a.1. The halogendiacid compound is treated with an equimolar amount of an agent activating the carboxyl group, under the conditions previously described in 1a.1., and then it is reacted with the reactive function of the steroid molecule. In the subsequent step the second carboxylic function is treated with an activating agent, as previously made for the first, and reacted with the precursor compound of B<sub>1</sub> according to the following scheme:



The halogen atom is then substituted with the  $\text{ONO}_2$  group as above mentioned.

3. Synthesis of the nitroso ( $s=1$ ) derivatives of formula (I).

3a.1 The compound of formula (1A.1b) wherein  $R_3 = \text{OH}$  is reacted with sodium nitrite in a solvent formed of a mixture of water with tetrahydrofuran in the presence of hydrochloric acid. The reaction is widely illustrated in the prior art. The general scheme is the following:



3a.2 If the compound obtained at the end of step A has formula (IA.2) the corresponding nitroso derivative is obtained by treating an hydroxyacid of formula  $\text{HO-X}_1\text{-COOH}$ ,  $X_1$  being as above defined, first with an agent activating the carboxyl group, as described in 1a.1, then with 1A.2 and the resulting product with sodium nitrite as described in 3a.1.


3b.1 To obtain the nitroso derivative starting from the compound of formula  $\text{R-T}_B\text{-X}_2\text{-XH}$  (1B.1) obtained at the end of the synthesis described in 1b.1, the compound (1B.1) is reacted with an hydroxyacid as described in 3a.2.

3b.2 To obtain the nitroso derivative from the compound of formula  $\text{R-T}_B\text{-X}_2\text{-COOH}$  (1B.2) obtained at the end of the synthesis described in 1b.2, the acid is transformed into the sodic salt and reacted with a compound  $\text{Hal-X}_1\text{-OH}$ , as

previously described, and the obtained alcohol is treated as described in 3a.1.

4) Synthesis of the nitroso derivatives of formula (II)

4a.1 When the steroid reactive function is a carboxylic group (general formula R-COOH) and the precursor compound of B<sub>1</sub> contains only one functional reactive group of formula XH, X being as above defined, R-COOH is initially converted into the corresponding acyl-halide or treated with an agent activating the carboxyl group as described in 1a.1, and then reacted with the HX function of an hydroxy-acid compound, said function being equal to or different from that present on the precursor compound of B<sub>1</sub>, said hydroxy-acid having the formula:




wherein X<sub>1</sub>' is Y' as above defined without the oxygen atom through which the -NO group is linked, X is as above defined.


The free carboxylic function of the compound resulting from the reaction with the steroid molecule is reacted with the function present in the molecule of the precursor compound of B<sub>1</sub>, as previously illustrated in 1a.1 for the reaction between the R-COOH acid and the precursor compound of B. In the final step the alcohol is transformed into the nitroso-derivative as described in

3a.1.


The reaction scheme is the following, exemplified starting from the  $\text{RCOCl}$  acid halide:




- 4b. When the reactive steroid function is a OH group and the precursor compound of  $\text{B}_1$  contains a reactive group of general formula  $\text{XH}$ ,  $\text{HX}$  in which  $\text{X}$  is as above defined being equal to or different from  $\text{OH}$ , the synthesis is carried out starting from an hydroxydiacid compound of formula



$\text{X}_1'$  being as above defined, said hydroxydiacid compound is treated with an equimolar amount of an agent activating the carboxyl group, under the conditions previously described in 1a.1., and then it is reacted with the steroid reactive function. In the subsequent step the second carboxylic function is treated with an activating agent, as previously made for the first one, and reacted with the precursor compound of  $\text{B}_1$  according to the following scheme:





The obtained compound is reacted as described in 3a.1.

The compounds object of the present invention are formulated in the corresponding pharmaceutical compositions for parenteral, oral and topic use according to the well known methods in the art, together with the usual excipients; see for example the volume "Remington's Pharmaceutical Sciences 15a Ed."


The amount on molar basis of the active principle in these formulations is the same, or lower, in comparison with that used of the corresponding precursor drug.

The daily administrable doses are those of precursor drugs, or in the case lower. The daily doses can be found in the publications of the field, such as for example in "Physician's Desk reference".


The following examples have the purpose to illustrate the invention and are not to be considered as limitative of the same.

#### EXAMPLE 1


Preparation of 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dihydroxycolan-24-oiloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitroxybutyl ester



wherein the precursor steroid is ursodesoxycholic acid of formula (XL), the precursor of B is ferulic acid of formula (DII):



(XL)



(DII)

a) synthesis of the 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid 4-bromobutyl ester

To a solution of 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid (10 g, 51.5 mmol) in THF (400 ml) triphenylphosphine (2.7 g, 10.3 mmol) and carbon tetrabromide (34.16 g, 10.3 mmol) are added and the solution is left at room temperature,

under magnetic stirring, for 48 hours. The solid is filtered and then evaporated at reduced pressure. The obtained crude product is purified by chromatography on silica gel eluting with n-hexane/ethyl acetate 7/3. 9 g of 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid 4-bromobutyl ester are obtained. M.p. = 86-89°C.

b) Synthesis of the 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dihydroxycolan-24-oiloxyl]-3-methoxyphenyl]-2-propenoic acid 4-bromobutyl ester

To a solution of (3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dehydroxycolan-24-oic acid (2.9 g, 7.38 mmol) dissolved in chloroform (25 ml) and dimethylacetamide (25 ml), 3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid 4-bromobutyl ester (2.73 g, 8.28 mmol) is added under stirring. To the solution cooled at 0°C, kept under stirring, N,N'-dicyclohexylcarbodiimide (2 g, 9.7 mmol) and 4-dimethylamino pyridine (100 mg, 0.81 mmol) are added. After 1 hour the mixture is heated to room temperature, after 24 hours the precipitate is filtered, the solvent is evaporated at reduced pressure. The residue is treated with ethyl acetate (150 ml) and washed with water (3X 100 ml). After the organic phase is anhydriified with sodium sulphate the solvent is evaporated. The obtained crude product is purified by chromatography on silica gel column eluting with n-hexane/ethyl acetate 1/9. 2.5 g of 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dihydroxycolan-24-oiloxyl]-3-methoxyphenyl]-2-propenoic acid 4-bromobutyl ester are obtained.

c) Synthesis of the 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dihydroxycolan-24-oiloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitroxybutyl ester


To a solution of 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dehydroxycolan-24-oiloxy]-3-methoxyphenyl]-2-propenoic acid 4-bromobutyl ester (2.3 g, 3.27 mmols) in acetonitrile (20 ml) and tetrahydrofuran (5 ml) silver nitrate (0.84 g, 4.94 mmols) is added under stirring and the mixture is heated to 80°C under magnetic stirring for 6 hours. When the reaction is over the precipitate is filtered and the solvent is evaporated. The obtained crude product is purified by chromatography on silica gel column eluting with methylene chloride/ethyl acetate 3/7. 1.5 g of 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\beta$ )-3,7-dehydroxycolan-24-oiloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitroxybutyl ester are obtained. Total yield 32%.

#### Elementary analysis


Calculated	C	66.55%	H	8.08%	N	2.04%
Found	C	66.59%	H	8.14%	N	1.99%

#### EXAMPLE 2


Preparation of 3-[4-[(3 $\alpha$ ,5 $\beta$ ,7 $\alpha$ )-3,7-dihydroxycolan-24-oiloxy]-3-methoxyphenyl]-2-propenoic acid 4-nitroxybutyl ester



wherein the precursor steroid is chenodeoxycholic acid of formula (XLI) and the B precursor is ferulic acid of formula (DII)



(XLI)



(DII)

The compound is prepared following the procedure reported in Example 1. Total yield 28%.


#### Elementary analysis

Calculated      C 66.55% H 8.08% N 2.04%

Found            C 66.64%      H 8.13%      N 1.94%


#### EXAMPLE 3

Preparation of (11 $\beta$ )-11,17-dihydroxy-21[N-acetyl-S-(4-nitroxybutyryl)cysteinyl]-pregn-1,4-diene-3,20-dione




wherein the precursor steroid is prednisolone of formula (XLII)

and the precursor of B is N-acetyl cysteine of formula (CVIII)



(XLII)



(CVIII)

a) Synthesis of N-acetyl-S-(4-bromobutyroyl)cysteine

A solution of 4-bromobutyric acid (5.1 g, 30.6 mmol) and 1,1'-carbonyldiimidazol (5.61 g, 34.6 mmol) in chloroform (50 ml) is left at room temperature under stirring for 1 hour. To the reaction mixture N-acetyl cysteine (5 g, 30.6 mmol) dissolved in N,N-dimethylformamide (5 ml) and sodium ethylate (50 mg) is added under stirring. After 24 hours the solution is washed with HCl 1% and brine, the organic phase is anhydriified with sodium sulphate and evaporated at reduced pressure. The obtained crude product is purified by chromatography on silica gel column, eluting with ethyl acetate/chloroform 7/3. N-acetyl-S-(4-bromobutyroyl)cysteine is obtained.

b) Synthesis of (11 $\beta$ )-11,17-Dihydroxy-21[N-acetyl-S-(4-bromobutyroyl)cysteinyloxy]-pregn-1,4-diene-3,20-dione

To a solution of N-acetyl-S-(4-bromobutyroyl)cysteine (2.7 g, 8.64 mmol) and (11 $\beta$ )-11,17,21-trihydroxypregn-1,4-diene-3,20-dione (3.2 g, 8.86 mmol) in tetrahydrofuran (100

ml) cooled at 0°C and kept under stirring, N,N'-dicyclohexylcarbodiimide (1.9 g, 9.2 mmol) and 4-dimethylaminopyridine (100 mg, 0.8 mmol) are added. After 1 hour the mixture is heated to room temperature, after 24 hours the precipitate is filtered, the solvent is evaporated at reduced pressure. The residue is treated with ethyl acetate (150 ml) and washed with water (3X 100 ml). After having anhydried the organic phase with sodium sulphate the solvent is evaporated. The obtained crude product is purified by chromatography on silica gel column eluting with chloroform/ethyl acetate 3/7. 0.94 g of (11 $\beta$ )-11,17-dehydroxy-21[N-acetyl-S-(4-bromobutyryl)cysteinyloxy]-pregn-1,4-diene-3,20-dione are obtained.

c) Synthesis of (11 $\beta$ )-11,17-Dihydroxy-21[N-acetyl-S-(4-nitroxybutyryl)cysteinyloxy]-pregn-1,4-diene-3,20-dione

To a solution of (11 $\beta$ )-11,17-dehydroxy-21[N-acetyl-S-(4-bromobutyryl)cysteinyloxy]-pregn-1,4-diene-3,20-dione (0.8 g, 1.28 mmol) in acetonitrile (10 ml) and tetrahydrofuran (5 ml) silver nitrate (0.4 g, 2.35 mmol) is added under stirring and the mixture is heated to 80°C under magnetic stirring for 20 hours. At the end of the reaction the precipitate is filtered and the solvent is evaporated. The obtained crude product is purified by chromatography on silica gel column eluting with methylene chloride/ethylacetate 3/7. (11 $\beta$ )-11,17-dehydroxy-21[N-acetyl-S-(4-nitroxybutyryl)cysteinyloxy]-pregn-1,4-diene-


3,20-dione is obtained. Total yield 12%.

Elementary analysis


Calculated	C 56.59%	H 6.33%	N 4.40%	S 5.04%
Found	C 56.63%	H 6.38%	N 4.36%	S 5.01%

#### EXAMPLE 4


Preparation of (11 $\beta$ )-11,17-Dihydroxy-21[N-acetyl-S-(4-nitroxybutyryl)cysteinyl]-pregn-4-ene-3,20-dione



wherein the precursor steroid is hydrocortisone of formula (XLI<sup>III</sup>) and the precursor of B is N-acetyl cysteine of formula (CVI<sup>III</sup>)



(XLI<sup>III</sup>)



(CVI<sup>III</sup>)

The compound is prepared according to the procedure reported in Example 3. Total yield 15%.


## Elementary analysis

Calculated	C 56.37%	H 6.78%	N 4.39%	S 5.02%
------------	----------	---------	---------	---------


Found	C 56.39%	H 6.81%	N 4.31%	S 4.93%
-------	----------	---------	---------	---------

EXAMPLE 5


Preparation of (11 $\beta$ ,16 $\alpha$ )-9-Fluoro-11,17-dihydroxy-21[N-acetyl-S-(4-nitroxybutyryl)cysteinyloxy]-16-methylpregn-1,4-diene-3,20-dione



wherein the precursor steroid is desamethasone of formula (XLIV) and the precursor of B is N-acetyl cysteine of formula (CVIII)



(XLIV)



(CVIII)

The compound is prepared according to the procedure reported in Example 3. Total yield 17%.

## Elementary analysis

Calculated	C 55.68%	H 6.18%	N 4.19%	S 4.79%
------------	----------	---------	---------	---------

Found                    C 55.72%    H 6.22%    N 4.15%    S 4.75%

PHARMACOLOGICAL TESTS

EXAMPLE

Acute Toxicity

Acute toxicity has been evaluated by administering to a group of 10 rats weighing 20 g a single dose of each of the tested compounds, by cannula, by os in an aqueous suspension of carboxymethylcellulose 2% w/v.

The animals are kept under observation for 14 days. In no animal of the group toxic symptoms appeared even after a 100 mg/Kg dose administration.

EXAMPLE F1

Experimental in vivo model with N<sup>w</sup>-nitro-L-arginine-methyl ester (L-NAME): effect of the precursor steroids and of the corresponding compounds according to the present invention on the endothelial dysfunction induced by L-NAME.

The experimental model adopted is according to J. Clin. Investigation 90, 278-281, 1992.

The endothelial dysfunction is evaluated by determining the damage the hepatic damage (GPT increase), and the vascular endothelium or cardiovascular damage (blood hypertension) induced by L-NAME administration.

The animals (Long Evans rats, average weight 350-450 g) are divided in groups as herein below described. The group receiving L-NAME is treated for 4 weeks with said compound

dissolved at the concentration of 400 mg/litre in drinking water. The following groups (No. 10 animals for group) are constituted:

A) Control groups:

1° group: treatment: only carrier (physiologic solution),

2° group: treatment: carrier + L-NAME,

B) Groups treated with the drug:

3° group: treatment: carrier + drug,

4° group: treatment: carrier + drug + L-NAME.

The drugs screened in the test are hydrocortisone, desamethasone, prednisolone, chenodeoxycholic acid, ursodesoxycholic acid and the corresponding derivatives according to the present invention.

In those groups of rats treated, respectively, with hydrocortisone, desamethasone, prednisolone and thereof corresponding compounds according to the present invention, the blood-pressure is determined.

In those groups of rats treated, respectively, with ursodesoxycholic acid and chenodeoxycholic acid and thereof corresponding compounds according to the present invention, GPT is determined.

Each drug is administered by intraperitoneal route once a day for 4 weeks.

At the end of the four weeks access to water is prevented and after 24 hours the animals are sacrificed.

Four hours after the last administration the blood-pressure is determined.

Damage to the vascular endothelium is determined, as said by the cardiovascular effects induced by L-NAME (increase of the blood pressure). The hepatic damage is determined by evaluation of the glutamic-pyruvic transaminase (GPT increase) after sacrifice.

Results are reported in Tables I and II. The % blood-pressure and GPT values are referred to the corresponding value found in the animals of the 1st control group. The average value of the blood pressure in this group was of 105 mmHg.

The results obtained show that the steroidal precursors cause hepatic damage (ursodesoxycholic acid and chenodeoxycholic acid) and arterial hypertension (hydrocortisone, desamethasone, prednisolone). GPT and blood pressure values of the treated rats are higher compared both with the corresponding groups treated with drug in the absence of L-NAME and with the controls treated with L-NAME. The products of the invention are instead better tolerated in comparison with the corresponding precursors, even in animals not pretreated with L-NAME.

#### EXAMPLE F2

Test 4: inhibition of the radical production from DPPH of some substances used to prepare the precursors of B or B1

The method is based on a colorimetric test in which DPPH

(2,2-diphenyl-1-picryl-hydrazyl) is used as the compound-forming radicals (M.S. Nenseter et Al., Atheroscler. Thromb. 15, 1338-1344, 1995).

Solutions in methanol of the tested substances at a final concentration 100  $\mu$ M are initially prepared. 0.1 ml of each of these solutions are added to aliquots of 1 ml of a methanol solution 0.1 M of DPPH and then the final volume is brought to 1.5 ml. After having stored the solutions at room temperature away from light for 30 minutes, the absorbance at the wave length of 517 nm is read. It is determined the absorbance decrease with respect to the absorbance of a solution containing the same concentration of DPPH.

The efficacy of the test compound to inhibit the production of radicals, otherwise said antiradical activity, is expressed by the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are, respectively, the absorbance values of the solution containing the test compound together + DPPH and of the solution containing only DPPH.

The compound to be used as precursor of B or  $B_1$  according to the present invention meets test 4 if it inhibits radical production from DPPH in a percent equal to or higher than 50%.

In Table III are reported the results obtained in said test with the following compounds: N-acetylcysteine, cysteine, ferulic acid, (L)-carnosine, gentisic acid, 4-thiazolidin

carboxylic acid and 2-oxo-4-thiazolidincarboxylic acid.

Table III shows the following:

- N-acetylcysteine, cysteine, ferulic acid, (L)-carnosine, gentisic acid meet test 4 since they inhibit the production of radicals induced by DPPH to an extent higher than 50%. Therefore they can be used as precursors of the B compound in the synthesis of the compounds according to the present invention.
- 4-thiazolidin carboxylic acid and the 2-oxo-4-thiazolidin carboxylic acid do not meet test 4 since they do not inhibit radical production from DPPH. Therefore they can be used as precursors of B or B<sub>1</sub> if they meet test 5.

#### EXAMPLE F3

Test 5: Inhibition of the radical production from Fe<sup>II</sup> from compounds used as precursors of B, B<sub>1</sub> or C = -T<sub>C</sub>-Y-H.

0.1 ml aliquots of 10<sup>-4</sup> M methanolic solutions of 4-thiazolidin carboxylic acid and 2-oxo-4-thiazolidin carboxylic acid are added to test tubes containing an aqueous solution formed by mixing 0.2 ml of 2 mM desoxyribose, 0.4 ml of buffer phosphate pH 7.4 100 mM and 0.1 ml of 1 mM Fe<sup>II</sup>(NH<sub>4</sub>)<sub>2</sub>(SO<sub>4</sub>)<sub>2</sub> in 2mM HCl. The test tubes are then kept at a temperature of 37°C for one hour. Then in each test tube 0.5 ml of a 2.8% solution in trichloroacetic acid in water and 0.5 ml of an aqueous solution 0.1 M thiobarbituric acid are added in the order. A reference blank is constituted by substituting the above 0.1 ml

aliquots of the test compound methanolic solutions with 0.1 ml of methanol. The test tubes are closed and heated in an oil bath at 100°C for 15 minutes. A pink coloration develops the intensity of which is proportional to the quantity of desoxyribose undergone to radical oxidative degradation. The solutions are cooled at room temperature and their absorbances at 532 nm are read against the blank.

The inhibition induced by the precursor of B or B<sub>1</sub> or C = -T<sub>C</sub>-Y-H (wherein the free valence is saturated as above defined) with respect to radical production from Fe<sup>II</sup> is determined as a percentage by means of the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein A<sub>s</sub> and A<sub>c</sub> are respectively the absorbance values of the solution containing the tested compound + the iron salt and that of the solution containing only the iron salt.

The results are reported in Table IV, which shows that both acids meet test 5 since they inhibit radical production from Fe<sup>II</sup> in a percentage higher than 50%. Therefore both 4-thiazolidin carboxylic acid and 2-oxo-4-thiazolidin carboxylic acid can be used as precursors of B, B<sub>1</sub> or C = -T<sub>C</sub>-Y-H for obtaining compounds of the present invention.

#### EXAMPLE F4

Example F1 was repeated with three groups of rats (each group of of ten animals), one control group not receiving L-NAME and two groups receiving L-NAME, and i.p. administered as it

follows :

- a. control group (not receiving L-NAME) : the carrier (physiologic solution),
- b. 1st group receiving L-NAME (group b - comparative ) administered at the same time with 25 mg/Kg (0.064 mmoles/Kg) of dexamethasone + 10.4 mg/Kg (0.064 mmoles/Kg) of N-acetylcysteine in the same above carrier,
- c. 2nd group receiving L-NAME (group c) administered with 42.5 mg/Kg (0.064 mmoles/Kg) of the dexamethasone derivative according to the invention (ref. ex. 5) in the same above carrier.

In this experiment vascular tolerability, i.e. the rise in blood pressure (vascular damage) was determined in the animals of groups b and c and expressed as percentages to that of the control group a, assumed to be 100 %.

The results are reported in Table V and show that the mixture administered to group b (comparative) induced in the animals an higher blood pressure increase than the compound of the invention (group c).

#### EXAMPLE F5

Example F1 was repeated with three groups of rats (each group of of ten animals), one control group not receiving L-NAME and two groups receiving L-NAME, and i.p. administered as it follows :

- a. control group (not receiving L-NAME) : the carrier

(physiologic solution),

- b. 1st group receiving L-NAME (group d - comparative ) administered at the same time with 100 mg/Kg (0.25 mmol/Kg) of ursodesoxycholic acid + 49.5 mg/Kg (0.25 mmol/Kg) of ferulic acid in the same above carrier,
- c. 2nd group receiving L-NAME (group e) administered with 175 mg/Kg (0.25 mmol/Kg) of the ursodesoxycholic derivative according to the invention (ref. ex. 1) in the same above carrier.

In this experiment hepatic tolerability, i.e. the rise in GPT (hepatic damage) was determined in the animals of groups d and e and expressed as percentages to that of the control group a, assumed to be 100 %.

The results are reported in Table VI and show that the mixture administered to group d (comparative), induced in the animals an higher GPT increase than the compound of the invention (group e).

Table I

<p>Study of vascular tolerability of hydrocortisone, dexamethasone and prednisolone, and of the corresponding derivatives according to the invention, in animals (rats) both not treated and treated with L-NAME. Vascular tolerability is indicated as % variation of the blood pressure (hypertension) with respect to the controls not treated with L-NAME and treated with the only carrier (physiological solution)</p>				
Compound	Animals non treated with L-NAME		Animals treated with L-NAME	
	dose mg/Kg i.p.	Blood pressure variation %	dose mg/Kg i.p.	Blood pressure variation %
carrier	-	100	-	140
hydrocortisone	10	115	5	160
hydrocortisone der. Ex. 4	10	98	5	120
dexamethasone	5	125	25	170
dexamethasone der. Ex. 5	5	103	25	125
prednisolone	10	119	15	165
prednisolone der. Ex. 3	10	102	15	110

Table II

Study of hepatic damage, determined by GPT assay, of chenodeoxycholic acid and ursodesoxycholic acid, and of the corresponding derivatives according to the invention, in animals (rats) both not treated and treated with L-NAME. The % variation of GPT with respect to the controls not treated with L-NAME and treated with the only carrier (physiological solution)				
Compound	animals non treated with L-NAME		Animals treated with L-NAME	
	dose mg/Kg i.p.	GPT var. %	dose mg/Kg i.p.	GPT var. %
carrier	-	100	-	230
chenodeoxycholic acid	100	150	100	350
chenodeoxycholic acid der. Ex. 2	100	105	100	130
ursodesoxycholic acid	100	130	100	276
ursodesoxycholic acid der. Ex. 1	100	103	100	123

Table III

Test 4: Screening of the effectiveness of some substances to inhibit radical production from DPPH.	
Compound	% inhibition radical production from DPPH
Solvent	0
N-acetylcysteine	100
Cysteine	100
Ferulic acid	100
(L)-carnosine	80
Gentisic acid	80
2-oxo-4-thiazolidin carboxylic acid	0
4-thiazolidin carboxylic acid	0

Table IV

Test 5 : study on the effectiveness of the listed substances to inhibit radical production induced by Fe <sup>II</sup>	
Compound	% Radical Inhibition from Fe <sup>II</sup>
White	0
2-oxo-4-thiazolidin carboxylic acid	100
4-thiazolidin carboxylic acid	100

Table V


<p>Study of vascular tolerability in animals (rats) treated with L-NAME and i.p. administered with a mixture of dexamethasone + N-acetylcysteine and with the derivative of dexamethasone of ex. 5 according to the invention. Vascular tolerability is indicated as % variation of the blood pressure (hypertension) with respect to the controls not treated with L-NAME and treated with the only carrier.</p>		
Compound	dose mg/Kg i.p.	Blood pressure variation %
controls	-	100
group b - comparative dexamethasone (A)+ N-acetyl cysteine (B)	25(A)+10.4(B)	170
group c dexamethasone der. Ex. 5	42.5	125

Table VI

<p>Study of hepatic tolerability in animals (rats) treated with L-NAME and i.p. administered with a mixture of ursodesoxycholic acid + ferulic acid and with the derivative of ursodesoxycholic acid of ex. 1 according to the invention. Hepatic damage is indicated as % variation of GPT with respect to the controls not treated with L-NAME and treated with the only carrier.</p>		
Compound	dose mg/Kg i.p.	GPT variation %
controls	-	100
group d - comparative ursodesoxycholic acid (C)+ ferulic acid (D)	100(C)+49.5(D)	180
group e ursodesoxycholic acid der. ex. 1	175	123

## CLAIMS

1. Steroidal compounds or their salts having the following general formulas (I) and (II):



wherein:

s = is an integer equal to 1 or 2, preferably s = 2;

b0 = 0 or 1;

A = R—, wherein R is the steroidal drug radical as defined hereunder,

B = -T<sub>B</sub>-X<sub>2</sub>-T<sub>BI</sub>- wherein

T<sub>B</sub> and T<sub>BI</sub> are equal or different;

T<sub>B</sub> = (CO) when the reactive function in the precursor steroid is -OH; T<sub>B</sub> = X when the reactive function in the precursor steroid is -COOH;

X = O, S, NR<sub>1C</sub>, R<sub>1C</sub> is H or a linear or branched alkyl having from 1 to 5 carbon atoms, or a free valence;


T<sub>BI</sub> = (CO)<sub>tx</sub> or (X)<sub>txx</sub>, wherein tx and txx have the value of 0 or 1; with the proviso that tx = 1 when txx = 0, tx = 0 when txx = 1; X is as above defined;

X<sub>2</sub> is a bivalent bridging group as defined hereunder;

C is the bivalent radical -T<sub>C</sub>-Y- wherein

T<sub>C</sub> = (CO) when tx = 0, T<sub>C</sub> = X when txx = 0, X being as above defined;

Y is:



wherein:

$n_{IX}$  is an integer between 0 and 3, preferably 1;


$n_{IIX}$  is an integer between 1 and 3, preferably 1;

$R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$ , equal to or different from each other are H or a linear or branched  $C_1$ - $C_4$  alkyl; preferably  $R_{TIX}$ ,  $R_{TIX'}$ ,  $R_{TIIX}$ ,  $R_{TIIX'}$  are H.


$Y^3$  is a saturated, unsaturated or aromatic heterocyclic ring containing at least one nitrogen atom, said ring having 5 or 6 atoms,

or Y is  $Y_0$ , selected from the following:


- an alkyleneoxy group  $R'O$  wherein  $R'$  is linear or when possible branched  $C_1$ - $C_{20}$ , preferably having from 1 to 6 carbon atoms, or a cycloalkylene having from 5 to 7 carbon atoms, in the cycloalkylenic ring one or more carbon atoms can be substituted by heteroatoms, the ring can have side chains of  $R'$  type,  $R'$  being as above defined; or




wherein  $n_3$  is an integer from 0 to 3 and  $n_3'$  is an integer from 1 to 3;



wherein  $n_3$  and  $n_3'$  have the above mentioned meaning



wherein  $\text{nf}'$  is an integer from 1 to 6 preferably from 1 to 4;



wherein  $\text{R}_{1\text{f}} = \text{H}, \text{CH}_3$  and  $\text{nf}$  is an integer from 1 to 6; preferably from 1 to 4;

preferably  $\text{Y} = -\text{Y}_0 = \text{R}'\text{O}-$  wherein  $\text{R}'$  is as above defined; preferably  $\text{R}'$  is a  $\text{C}_1\text{-C}_6$  alkyl;



wherein:




wherein  $T_{CI}$  and  $T_{CII}$  are equal or different,

$T_{CI} = (\text{CO})$  when the reactive function of the precursor steroid is  $-\text{OH}$ ,  $T_{CI} = \text{X}$  when the reactive function of the precursor steroid is  $-\text{COOH}$ ,  $\text{X}$  being as above defined;


$T_{CII} = (\text{CO})_{tI}$  or  $(\text{X})_{tII}$ , wherein  $tI$  and  $tII$  have the 0 or 1 value; with the proviso that  $tI = 1$  when  $tII = 0$ ;  $tI = 0$  when  $tII = 1$ ;  $\text{X}$  is as above defined;

$\text{Y}'$  is as  $\text{Y}$  above defined, but with three free valences instead of two, preferably selected from the following:


- a  $-\text{R}'\text{O}-$  group wherein  $\text{R}'$  is  $\text{C}_{1-20}$  linear or branched, preferably having from 1 to 6 carbon atoms, or a saturated ring having from 5 to 7 carbon atoms, optionally substituted; or




wherein  $n3$  is an integer from 0 to 3 and  $n3'$  is an integer from 1 to 3;




wherein  $n_3$  and  $n_3'$  have the above mentioned meaning;




wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;



wherein  $n_3'$  is an integer from 1 to 6 preferably from 1 to 4; wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;



wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;




wherein  $\text{R}_{1f} = \text{H}, \text{CH}_3$  and  $n_4$  is an integer from 1 to 6; preferably from 1 to 4; wherein one hydrogen atom on one of the carbon atoms is substituted by a free valence;

preferably  $\text{Y}' = - \text{R}'\text{O}-$  wherein  $\text{R}'$  is a linear or branched  $\text{C}_2 - \text{C}_4$ , the oxygen which in  $\text{Y}'$  is covalently linked to the  $-\text{N}(\text{O})_s$  group finds at the end of the free bond indicated in  $\text{C}_1$  formula;

or  $\text{Y}' = \text{Y}_0$  as defined in (I) but with three free

valences instead of 2;




wherein  $X_{2a}$  is a monovalent radical,

$T_{BII} = (CO)$  when  $tI = 0$ ,  $T_{BII} = X$  when  $tII = 0$ ,  $X$  being as above defined;

- $X_2$ , bivalent radical is such that the corresponding B precursor:  $-T_B-X_2-T_{BI}-$  meets test 4 or test 5, precursor in which the  $T_B$  and  $T_{BI}$  free valences are each saturated with OZ, with Z or with  $-Z^I-N-Z^{II}$ ,  $Z^I$  and  $Z^{II}$  being equal or different and have the Z values as above defined, depending on whether  $T_B$  and/or  $T_{BI} = CO$  or X, in connection with the values of t, t', tx and txx;
- the C precursor when  $b0 = 0$  is of  $-T_C-Y-H$  type wherein the  $T_C$  free valence is saturated with OZ, Z, or with  $-Z^I-N-Z^{II}$ ,  $Z^I$  and  $Z^{II}$  being as above defined, meets test 5;
- $X_{2a}$  monovalent radical, such that the corresponding precursor of  $B_1$   $-T_{BII}-X_{2a}$  meets test 4 or test 5, precursor wherein the  $T_{BII}$  free valence is saturated with OZ or with Z or with  $-Z^I-N-Z^{II}$ ,  $Z^I$  and  $Z^{II}$  being equal or different and having the Z values as above defined, depending on whether  $T_{BII} = CO$  or X, in connection with the tI and tII values;


A = R- has the following structure:



wherein in substitution of the hydrogens of the CH groups or of the two hydrogens of the CH<sub>2</sub> groups mentioned in the general formula, the following substituents can be present:

in position 1-2: there may be a double bond;

in position 2-3: there may be the following substituent:



in position 2: there may be Cl, Br;

in position 3: there may be CO, -O-CH<sub>2</sub>-CH<sub>2</sub>-Cl, OH;

in position 3-4: there may be a double bond;

in position 4-5: there may be a double bond;

in position 5-6: there may be a double bond;

in position 5-10: there may be a double bond;

in position 6: there may be Cl, F, CH<sub>3</sub>, -CHO;


in position 7: there may be Cl, OH;

in position 9: there may be Cl, F;

in position 11: there may be OH, CO, Cl, CH<sub>3</sub>;


in position 16: there may be CH<sub>3</sub>, OH, =CH<sub>2</sub>;

in position 17: there may be OH, CH<sub>3</sub>, OCO(O)<sub>ua</sub>(CH<sub>2</sub>)<sub>va</sub>CH<sub>3</sub>,  
C≡CH or



wherein ua is an integer equal to 0 or 1, va is an integer from 0 to 4;

in position 16-17: there may be the following groups:




R and R', equal to or different from each other, can be hydrogen or linear or branched alkyls from 1 to 4 carbon atoms, preferably R = R' = CH<sub>3</sub>;


R" is  $-(CO-L)_t-(L)_{t2}-(XO^I)_{t1}-$

wherein t, t1 and t2 are integers equal to or different from each other, equal to 0 or 1, with the proviso that when t = 0 t2 = 1 and when t = 1 t2 = 0, and that t and t1, or t2 and t1, cannot contemporaneously be equal to 0 when A does not contain -OH groups;

the bivalent bridging group L is selected from:



wherein  $n_a$ ,  $n'_a$ , and  $n''_a$ , equal to or different from each other, are integers from 0 to 6, preferably 1-3;  $n_b$ ,  $n'_b$ ,  $n''_b$  and  $n'''_b$ , equal to or different from each other, are integers equal to 0 or 1;  $R_4$ ,  $R_5$ , equal to or different from each other, are selected from H, linear or branched alkyl from 1 to 5 carbon atoms, preferably from 1 to 3;  $X_0^I$  is X as above defined, but  $R_{1c}$  is a linear or branched alkyl from 1 to 10 carbon atoms, or equal to  $X_2^I$  wherein  $X_2^I$  is equal to OH, CH<sub>3</sub>, Cl, N(-CH<sub>2</sub>-CH<sub>3</sub>)<sub>2</sub>, SCH<sub>2</sub>F, SH, or



wherein test 4, which must be met by the precursors of B or B<sub>1</sub> with the free valences saturated as above defined, is the following: it is an analytical determination carried out by adding portions of methanol solutions of the precursor of B or B<sub>1</sub> at a 10<sup>-4</sup> M concentration, to a methanol solution of DPPH (2,2-diphenyl-1-picryl hydrazyl - free radical); after having maintained the solution at room temperature away from light for 30 minutes, it is read the absorbance at the wave length of 517 nm of the test solution and of a solution containing only DPPH in the same amount as in the

test solution, and then the inhibition induced by the precursor towards radical production by DPPH is calculated as a percentage by means of the following formula:

$$(1 - A_s/A_c) \times 100$$

wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the test compound + DPPH and that of the solution containing only DPPH; test 4 is met by B or  $B_1$  precursor compounds if the % inhibition as above defined is higher than or equal to 50%;


wherein test 5 is an analytical determination carried out by adding aliquots of  $10^{-4}$  M methanol solutions of the precursor of B or  $B_1$  or of  $C = -T_c-Y-H$ , having the free valence saturated as above indicated, to a solution formed by admixing a 2 mM solution of desoxyribose in water with 100 mM of phosphate buffer and 1 mM of the salt  $Fe^{II}(NH_4)_2(SO_4)_2$ ; after having thermostatted the solution at 37°C for one hour, aliquots of aqueous solutions of trichloroacetic acid 2.8% and of thiobarbituric acid 0.5 M are added, in the order, heating is effected at 100°C for 15 minutes and the absorbance of the tested solutions is then read at 532 nm; the inhibition induced by the precursor of B or  $B_1$  or  $C = -T_c-Y-H$  with respect to radical production by  $Fe^{II}$  is calculated as a percentage by means of the following formula:

$$(1 - A_s/A_c) \times 100$$


wherein  $A_s$  and  $A_c$  are respectively the absorbance values of the solution containing the tested compound and the iron salt and that of the solution containing only the iron salt, the compound meets test 5 when the inhibition percentage as above defined of the precursor of B or  $B_1$  or  $C = -T_c-Y-H$  is higher than or equal to 50%; provided that in the compounds of formula (I) are excluded the drugs with  $A = R-$  when  $b_0 = 0$  and  $C = -T_c-Y_0-$  wherein the free valence of  $Y_0$  is saturated as indicated above,  $s = 1$  or 2.

2. Compounds according to claim 1, wherein the precursor compound of B or  $B_1$  which meets test 4, is selected in the following classes:


- Aminoacids, selected from the following: L-carnosine (formula CI), anserine (CII), selenocysteine (CIII), selenomethionine (CIV), penicillamine (CV), N-acetyl-penicillamine (CVI), cysteine (CVII), N-acetyl-cysteine (CVIII), glutathione (CIX) or its esters, preferably ethyl or isopropyl ester:




(CI)




(CII)




(CIII)




(CIV)




(CV)




(CVI)



(CVII)




(CVIII)




(CIX)


- hydroxyacids, selected from the following: gallic acid (formula DI), ferulic acid (DII), gentisic acid (DIII), citric acid (DIV), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII), vanillic acid (DVIII), chlorogenic acid (DIX), kynurenic acid (DX), syringic acid (DXI):




(DI)




(DII)




(DIII)




(DIV)




(DV)




(DVI)




(DVII)




(DVIII)



(DIX)




(DX)




(DXI)

- Aromatic and heterocyclic mono- and polyalcohols,  
selected from the following: nordihydroguaiaretic


acid (EI), quercetin (EII), catechin (EIII), kaempferol (EIV), sulphurethyne (EV), ascorbic acid (EVI), isoascorbic acid (EVII), hydroquinone (EVIII), gossypol (EIX), reductic acid (EX), methoxyhydroquinone (EXI), hydroxyhydroquinone (EXII), propyl gallate (EXIII), saccharose (EXIV), vitamin E (EXV), vitamin A (EXVI), 8-quinolol (EXVII), 3-tert-butyl-4-hydroxyanisole (EXVIII), 3-hydroxyflavone (EXIX), 3,5-tert-butyl-p-hydroxytoluene (EXX), p-tert-butyl phenol (EXXI), timolol (EXXII), xibornol (EXXIII), 3,5-di-ter-butyl-4-hydroxybenzyl-thioglycolate (EXXIV), 4'-hydroxybutyranilide (EXXV), guaiacol (EXXVI), tocol (EXXVII), isoeugenol (EXXVIII), eugenol (EXXIX), piperonyl alcohol (EXXX), allopurinol (EXXXI), conyferyl alcohol (EXXXII), 4-hydroxyphenethyl alcohol (EXXXIII), p-coumaric alcohol (EXXXIV), curcumin (EXXXV):




(EI)




(EII)




(EI II)




(EIV)




(EV)




(EVI)




(EVII)




(EVIII)




(EIX)




(EX)




(EXI)




(EXII)




(EXIII)




(EXIV)




(EXV)




(EXVI)




(EXVII)




(EXVIII)




(EXIX)




(EXXI)




(EXX)




(EXXII)




(EXXIII)




(EXXIV)




(EXXV)




(EXXVI)




(EXXVII)




(EXXXI)




(EXXVIII)




(EXXIX)




(EXXX)




(EXXXII)



(EXXXIII)




(EXXXIV)




(EXXXV)


- aromatic and heterocyclic amines, selected from the following: N, N'-diphenyl-p-phenylenediamine (MI), ethoxyquin (MII), thionine (MIII), hydroxyurea (M-IV):




(MI)



(MII)



(MIII)




(MIV)


- Compounds containing at least a free acid function, selected from the following: 3,3'-thiodipropionic acid (NI), fumaric acid (NII), dihydroxymaleic acid (NIII), thiocctic acid (NIV), edetic acid (NV), bilirubin (NVI), 3,4-methylenedioxcinnamic acid (NVI-I), piperonylic acid (NVIII):



(NI)




(NII)




(NIII)




(NIV)




(NV)



(NVI)




(NVII)




(NVIII)

3. Compounds according to claim 1 wherein the precursor compound of B or B<sub>1</sub> meeting test 5 is selected from the following:


- Aminoacids: aspartic acid (PI), histidine (PII), 5-hydroxytryptophan (PIII), 4-thiazolidincarboxylic acid (PIV), 2-oxo-4-thiazolidincarboxylic acid (PV)




(PI)




(PII)



(PIII)




(PIV)




(PV)


mono and polyalcohols or thiols: 2-thiouracil (QI), 2-mercaptoethanol (QII), esperidine (QIII), secalciferol (QIV), 1- $\alpha$ -OH vitamin D2 (QV), flocalcitriol (QVI), 22-oxacalcitriol (QVII), the vitamin D3 derivative esterified with the vitamin A radical (QVIII), the formula (QIX) compound, 24,28-methylene-1 $\alpha$ -hydroxyvitamin D2 (QX) the compound derived from 1 $\alpha$ ,25-dehydroxyvitamin D2 (QXI), 2-mercaptoimidazol (QXII)








(QI)




(QII)




(QIII)







(QIX)



(QX)




(QXII)




(QXI)

- succinic acid (RI)



(RI)

4. Compounds according to claims 1-2 wherein the precursors of B and B<sub>1</sub> are those meeting test 4.
5. Compounds according to claims 1-4 wherein Y<sup>3</sup> in formula (III) is selected from the following:



6. Compounds according to claim 5 wherein Y<sup>3</sup> is Y12 (pyridyl)

substituted in positions 2 and 6.

7. Compounds according to claims 1-6 wherein in the precursor steroids  $R'' = -CO-CH_2OH$ ,  $-CH(CH_3)-CH_2-CH_2-COOH$ .
8. Compounds according to claims 1-7 wherein in the precursor steroids the hydroxyl function is in position 3 and/or in position 11, and/or having in  $R''$  an hydroxyl or carboxylic function in terminal position.
9. Compounds according to claims 1-8, wherein the precursor steroids are selected from the following: Budesonide, Hydrocortisone, Alclomethasone, Algestone, Beclomethasone, Betamethasone, Chloroprednisone, Clobetasol, Clobetasone, Clocortolone, Cloprednol, Cortisone, Corticosterone, Deflazacort, Desonide, Desoximethasone, Dexamethasone, Diflorasone Diflucortolone, Difluprednate, Fluazacort, Flucloronide, Flumethasone, Flunisolide, Fluocinolone Acetonide, Fluocinonide, Fluocortyn Butyl, Fluocortolone, Fluorometholone, Fluperolone Acetate, Fluprednidene Acetate, Fluprednisolone, Flurandrenolide, Formocortal, Halcinonide, Halobetasol Propionate, Halomethasone, Halopredone Acetate, Hydrocortamate, Loteprednol Etabonate, Medrysone, Meprednisone, Methylprednisolone, Momethasone Furoate, Paramethasone, Prednicarbate, Prednisolone, Prednisolone 25-Diethylaminoacetate, Prednisolone Sodium Phosphate, Prednisone, Prednival, Prednylidene, Rimexolone, Triamcinolone, Triamcinolone

Acetonide, 21-Acetoxypregnenolone, Cortivazol, Amcinonide, Fluticasone Propionate, Mazipredone, Tixocortol, Triamcinolone Hexacetonide, Ursodesoxycholic acid, Chenodeoxycholic acid, Mitatrienediol, Moxestrol, Ethynylestradiol, Estradiol, Mestranol.

10. Compounds or salts, or their compositions according to claims 1-9 for use as a medicament; provided that in the compounds of formula (I) are excluded the drugs with  $A = R^-$  when  $b_0 = 0$  and  $C = -T_c-Y_0$  wherein the free valence of  $Y_0$  is saturated as indicated above, and  $s = 1$  or  $2$ .
11. Use of the compounds or salts, or their compositions according to claims 1-9 for the preparation of drugs for the therapeutic stress oxidative use; in the compounds of formula (I) when  $b_0 = 0$  and  $C = -T_c-Y_0$  wherein the free valence of  $Y_0$  is saturated as indicated above,  $s = 1$  or  $2$ , the drug can be  $A = R^-$ .
12. Pharmaceutical formulations containing as active principle the compounds or their salts of claims 1-9.

# INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/EP 00/03238

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07J41/00 A61K31/575

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 15568 A (NICOX SA ;DEL SOLDATO PIERO (IT)) 16 April 1998 (1998-04-16) page 23, table examples 1,3	1,2,4, 7-12
Y	WO 97 41144 A (SEARLE & CO ;TJOENG FOE S (US); CURRIE MARK G (US); ZUPEC MARK E ( ) 6 November 1997 (1997-11-06) page 38, table page 4, paragraph 2; examples 21-26	1,2,4, 7-12
A	WO 97 21721 A (SEARLE & CO ;TJOENG FOE S (US); CURRIE MARK G (US); ZUPEC MARK E ( ) 19 June 1997 (1997-06-19) the whole document	1,2,4, 7-12
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

21 November 2000

Date of mailing of the international search report

20. 12 2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

# INTERNATIONAL SEARCH REPORT

Internat. Application No  
PCT/EP 00/03238

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 436 936 A (HOECHST AG) 17 July 1991 (1991-07-17) page 2, line 11 - line 12; examples 1,2,42,43 ---	1,2,4, 7-12
Y	EP 0 290 885 A (CHIESI FARMA SPA) 17 November 1988 (1988-11-17) page 3, line 12 - line 15 table I, compound IV; table II, compound VII; table III, compounds IV and VII ---	1,2,4, 7-12
Y	CEDERQVIST B ET AL: "DIRECT DEMONSTRATION OF NO FORMATION IN VIVO FROM ORGANIC NITRITES AND NITRATES, AND CORRELATION TO EFFECTS ON BLOOD PRESSURE AND TO IN VITRO EFFECTS" BIOCHEMICAL PHARMACOLOGY, GB, PERGAMON, OXFORD, vol. 47, no. 6, 1994, pages 1047-1053, XP000671053 ISSN: 0006-2952 page 1047, column 1, paragraph 2 -column 2, paragraph 1 ---	1,2,4, 7-12
Y	PATENT ABSTRACTS OF JAPAN vol. 007, no. 131 (C-169), 8 June 1983 (1983-06-08) & JP 58 045724 A (ORIZA YUKA KK), 17 March 1983 (1983-03-17) abstract ---	1,2,4, 7-12
Y	DE 196 34 793 A (SANOL ARZNEI SCHWARZ GMBH) 5 March 1998 (1998-03-05) page 2, line 2 - line 20; examples 1-3,5,7,8 ---	1,2,4, 7-12
Y	WO 88 00202 A (UNIV LOUIS PASTEUR DE STRASBOU) 14 January 1988 (1988-01-14) page 6, paragraphs 3,5 page 9, line 5 - line 9 ---	1,2,4, 7-12
Y	US 3 702 335 A (LAFILLE CLAUDE) 7 November 1972 (1972-11-07) column 10, paragraph 1; example 10 ---	1,2,4, 7-12
Y	CHEMICAL ABSTRACTS, vol. 118, no. 17, 26 April 1993 (1993-04-26) Columbus, Ohio, US; abstract no. 169434, HORI, KIMIHIKO ET AL: "21-Substituted steroids" XP002153479 abstract & JP 04 273892 A (KAO CORP., JAPAN) 30 September 1992 (1992-09-30) ---	1,2,4, 7-12
	-/--	

# INTERNATIONAL SEARCH REPORT

Internat. Application No

PCT/EP 00/03238

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHEMICAL ABSTRACTS, vol. 130, no. 21,  24 May 1999 (1999-05-24)  Columbus, Ohio, US;  abstract no. 276039,  BONN, R. ET AL: "SP/W-5186: a novel  sulfhydryl-containing NO donor"  XP002153480  abstract  &amp; CARDIOVASC. DRUG REV. (1998), 16(3),  195-211 ,</p>	<p>1,2,4,  7-12</p>



2

3

4

5



2

3

4

5

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal Application No

PCT/EP 00/03238

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9815568	A	16-04-1998	IT MI962048 A	06-04-1998
			AU 719250 B	04-05-2000
			AU 4780397 A	05-05-1998
			BR 9711586 A	24-08-1999
			CN 1253563 A	17-05-2000
			EP 0929565 A	21-07-1999
			HU 9904149 A	28-04-2000
WO 9741144	A	06-11-1997	US 5837698 A	17-11-1998
			AU 2922797 A	19-11-1997
			EP 0900233 A	10-03-1999
			JP 2000509072 T	18-07-2000
WO 9721721	A	19-06-1997	US 5707984 A	13-01-1998
			AT 195128 T	15-08-2000
			AU 1277297 A	03-07-1997
			CA 2239910 A	19-06-1997
			DE 69609632 D	07-09-2000
			DE 69609632 T	09-11-2000
			EP 0873351 A	28-10-1998
EP 0436936	A	17-07-1991	DE 4000397 A	11-07-1991
			AU 660248 B	15-06-1995
			AU 6189294 A	21-07-1994
			AU 652928 B	15-09-1994
			AU 6921791 A	05-09-1991
			CA 2033755 A	10-07-1991
			HU 210905 B	28-09-1995
			JP 4331284 A	19-11-1992
			NO 910075 A	10-07-1991
			NZ 236709 A	25-11-1992
			PT 96438 A, B	15-10-1991
			US 5508275 A	16-04-1996
			US 5318987 A	07-06-1994
			ZA 9100132 A	30-10-1991
EP 0290885	A	17-11-1988	IT 1204571 B	10-03-1989
			JP 63297383 A	05-12-1988
			US 4956384 A	11-09-1990
JP 58045724	A	17-03-1983	NONE	
DE 19634793	A	05-03-1998	NONE	
WO 8800202	A	14-01-1988	FR 2600653 A	31-12-1987
			AT 88479 T	15-05-1993
			DE 3785505 A	27-05-1993
			DE 3785505 T	28-10-1993
			EP 0254655 A	27-01-1988
			JP 1500430 T	16-02-1989
			JP 2667418 B	27-10-1997
			US 4913852 A	03-04-1990
US 3702335	A	07-11-1972	FR 2077750 A	05-11-1971
			BE 762732 A	16-07-1971
			CA 939335 A	01-01-1974
			DE 2100475 A	02-09-1971
			ES 387707 A	16-05-1973

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/03238

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3702335 A		GB 1324911 A	25-07-1973
JP 4273892 A	30-09-1992	NONE	